



Effects of Dexmedetomidine on Emergence Agitation and Recovery Quality Among Children Undergoing Surgery Under General Anesthesia: A Meta-Analysis of Randomized Controlled Trials

Xiaoli Yang^{1†}, Zhenyu Hu^{1†}, Fei Peng¹, Guangxiang Chen², Yu Zhou¹, Qiange Yang¹, Xiaoling Yang¹ and Maohua Wang^{1*}

¹ Department of Anesthesiology, The Affiliated Hospital of Southwest Medical University, Luzhou, China, ² Department of Radiology, The Affiliated Hospital of Southwest Medical University, Luzhou, China

OPEN ACCESS

Edited by:

Francesco Morini, Bambino Gesù Children Hospital (IRCCS), Italy

Reviewed by:

Luca Pio, Hôpital Robert Debré, France Piergiorgio Gamba, University of Padua, Italy

*Correspondence: Maohua Wang wangmaohua@swmu.edu.cn

[†]These authors have contributed

Specialty section:

equally to this work

This article was submitted to Pediatric Surgery, a section of the journal Frontiers in Pediatrics

Received: 05 July 2020 Accepted: 07 September 2020 Published: 13 November 2020

Citation:

Yang X, Hu Z, Peng F, Chen G, Zhou Y, Yang Q, Yang X and Wang M (2020) Effects of Dexmedetomidine on Emergence Agitation and Recovery Quality Among Children Undergoing Surgery Under General Anesthesia: A Meta-Analysis of Randomized Controlled Trials. Front. Pediatr. 8:580226. doi: 10.3389/fped.2020.580226 **Background:** Emergence agitation (EA) is one of the most common and intractable postoperative complications among children undergoing surgery under general anesthesia. Dexmedetomidine, an α (2)-adrenoceptor agonist, offers an ideal sedation, reduces preoperative anxiety, and facilitates smooth induction of anesthesia, and it is widely used in pediatric surgery. We aimed to evaluate the efficacy of dexmedetomidine for preventing emergence agitation in children after general anesthesia.

Methods: We comprehensively reviewed PubMed, Cochrane Library, EMBASE, and Web of Science databases to search all randomized controlled trials, published before April 22, 2020, investigating the efficacy of dexmedetomidine in preventing the emergence agitation in children after general anesthesia. The meta-analysis was performed using Review Manager 5.3. The primary outcome was the incidence of emergence agitation. Secondary outcomes included the number of patients requiring rescue analgesic, number of patients with postoperative nausea and vomiting, emergence time, extubation time, and time to discharge from the post-anesthesia care unit.

Results: We included a total of 33 studies, comprising 2,549 patients in this meta-analysis. Compared with saline, dexmedetomidine significantly reduced the emergence agitation incidence [risk ratio (RR) 0.29; 95% confidence interval (Cl) 0.22–0.37; p < 0.00001], incidence of postoperative nausea and vomiting (RR 0.46; 95% Cl 0.3–0.69; p = 0.0002), and the requirement of rescue analgesic (RR 0.29; 95% Cl 0.18–0.44; p < 0.00001). Furthermore, children in the dexmedetomidine group experienced a longer emergence time [mean difference (MD) 2.18; 95% Cl 0.81–3.56; p = 0.002] and extubation time (MD 0.77; 95% Cl 0.22–1.31; p = 0.006) compared with those in the saline group. However, no significant difference was observed in the time to discharge from the post-anesthesia care unit (MD 2.22; 95% Cl –2.29–6.74; p = 0.33) between the two groups. No significant differences were observed between the effects

1

of dexmedetomidine and other drugs like midazolam, propofol, fentanyl, tramadol, and clonidine in terms of the emergence agitation incidence and other parameters, except for the requirement of rescue analgesic (RR 0.45; 95% Cl 0.33–0.61; p < 0.00001).

Conclusions: Dexmedetomidine can prevent emergence agitation, relieves postoperative pain, decreases the requirement of rescue analgesic, and decreases the postoperative nausea and vomiting events.

Keywords: dexmedetomidine, emergence agitation, children, general anesthesia, meta-analysis

INTRODUCTION

Emergence agitation (EA) is a behavioral disturbance during the early post-anesthetic period, characterized by excitement, restlessness, disorientation, and other unusual behaviors, such as crying, shouting, kicking, inconsolability, and non-cooperation. EA incidence in children following sevoflurane anesthesia has been reported to be 10-80% (1, 2). EA is associated with the risk of self-harm, delayed discharge from the post-anesthesia care unit (PACU), extra burden on healthcare workers, increased parent dissatisfaction, and increased overall cost. Although the definition and criteria for EA are not clearly indicated, most children experiencing EA require a drug intervention to mitigate any threat to their safety. Patients with EA may unconsciously remove their endotracheal and stomach tubes, which can result in incision dehiscence, bleeding, urinary retention, and asphyxia. In addition, patients with EA often experience sympathetic excitation and instability of the circulatory system, which is dangerous if the patient is already having cardiovascular and cerebrovascular diseases. Several factors may cause EA, such as preschool age, preoperative anxiety, anesthetic, type of operation, and personal characteristics of the patient (3). Various drugs, including dexmedetomidine, midazolam, propofol, fentanyl, and melatonin have been investigated to prevent the EA incidence; however, the most favorable prophylactic treatment to decrease such incidence remains unknown. Among investigated drugs, dexmedetomidine is known as a highly selective α (2)adrenoceptor agonist with sedative, anxiolytic, sympatholytic, and analgesic-sparing effects, which causes minimal depression of the respiratory function (4). The efficacy of dexmedetomidine toward EA prevention has been investigated in several clinical trials, using different administration routes and different dosages. We aimed to assess the effect of dexmedetomidine on EA incidence in the present study.

MATERIALS AND METHODS

This meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (5). The study was registered on PROSPERO (registration number: CRD42020187711).

Criteria for Study Consideration

The trials selected for this meta-analysis met the following inclusion criteria:

- (i) randomized controlled trials;
- (ii) children aged between 0 and 18 years;
- (iii) involving comparisons of dexmedetomidine as the intervention drug, delivered via intravenous or intranasal routes, with normal saline and other drugs (such as, midazolam, propofol, and fentanyl);
- (iv) published in the English language;
- (v) involving EA assessment using evaluation scales, namely: five-point scale described by Cole, Aono four-point scale, Watcha four-point scale, a three-point scale, and Riker Sedation-Agitation Scale. Studies involving cardiac surgery were excluded.

Outcome Measures

The primary outcome was EA incidence. Secondary outcomes included the number of patients requiring rescue analgesia, number of patients with postoperative nausea and vomiting (PONV), emergence time, extubation time, and time to discharge from the PACU.

Search Strategy

PubMed, Cochrane Library, EMBASE, and Web of Science databases were comprehensively reviewed to identify randomized controlled clinical trials, published before April 22, 2020, investigating the efficacy of dexmedetomidine in EA prevention among children undergoing surgery with general anesthesia. In addition, the reference list of all the included studies was analyzed for additional potential publications. The detailed search strategies for each database are available in the **Appendix**.

Data Extraction

Two experienced reviewers (Xiaoli Yang and Zhenyu Hu) independently screened the title and abstract of each literature to verify the suitability of the included trials. Data extraction was conducted independently by two reviewers using a standard data-collection form. Disagreements were resolved through discussion between the two reviewers and the corresponding author (Maohua Wang) to achieve a consensus. The following information was extracted from the included articles: primary author, publication year, country of the study, type of surgery, participant characteristics (age and sex), the administration route and dexmedetomidine dosage, control group's measure, scale, and criteria used for EA assessment.

Risk-of-Bias Assessment

Two reviewers (Xiaoli Yang and Zhenyu Hu) independently assessed the quality of the included trials according to the Cochrane Collaboration tool (Cochrane, London, UK) (6). The included trials were scored as low risk, unclear, or high risk after assessment of bias under the following domains: random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias), and other sources of bias. Disagreements were resolved through discussion between the two reviewers and the corresponding author.

Data Analysis

The meta-analysis was conducted using Review Manager (Version 5.3, Nordic Cochrane Center). The Cochran Q test



TABLE 1 | Characteristics of included studies.

Study ID	Age	Surgery type	Sample size	Anesthesia	Groups	Outcome
Nidhi 2013 (12)	8–12 Y	Corrective surgery	36	Sev, N ₂ O Intubation	DEX (9): 1 ug/kg iv followed by 0.5 ug/kg/h infusion; NS (9): volume-matched iv	ABCDE
Bi 2019 (36)	6–48 M	Fiberoptic bronchoscopy	40	Sev LMA	DEX (11):1 ug/kg intranasal; NS (11):0.01 ml/kg intranasal	ADE
Sun 2017 (30)	1–5 Y	Laparoscopic hernia repair	97	Sev LMA	DEX1(13):0.25 ug/kg iv; DEX2(14):0.5 ug/kg iv; DEX3(14):1 ug/kg iv; NS (15):2 ml iv	ADEF
Boku 2015 (37)	10-14 M	Palatoplasty	70	Sev, N ₂ O Intubation	DEX (17):6 ug/kg/h for 10 min, followed by 0.4 ug/kg/h; NS (17): volume-matched iv	AD
Mizrak 2011 (18)	4.5–11 Y	Strabismus surgery	60	Ketamine Intubation	DEX (19):0.5 ug/kg iv; Placebo (19)	AC
Erdil 2009 (10)	2–7 Y	Adenoidectomy	90	Sev, N ₂ O Intubation	DEX (19):0.5 ug/kg iv; Fentanyl (19):2.5 ug/kg iv; NS (19): iv	ADE
Guler 2005 (35)	3–7 Y	Adenotonsillectomy	60	Sev, N ₂ O Intubation	DEX (19):0.5 ug/kg iv; NS (19): volume-matched iv	ABDE
Cho 2020 (13)	24 M-12 Y	Tonsillectomy	66	Sev Intubation	DEX (21):0.3 ug/kg iv; Midazolam (22):0.03 mg/kg iv	ABCDF
Li 2016 (23)	4–6 Y	Tonsillectomy	80	Des Intubation	DEX (24):0.2 ug/kg/h; NS (24): volume-matched iv	ABCDF
Wei 2015 (9)	3–24 M	Cleft palate repair	40	Sev, Propofol Remifentanil Intubation	DEX (11):0.8 ug/kg/min; NS (11): volume-matched iv	ABDE
Bhat 2018 (26)	1–8 Y	Inguinal hernia	90	Sev, N ₂ O LMA	DEX1(19):0.5 ug/kg iv; DEX2(19):1 ug/kg iv; NS (19):5 ml iv	AEF
Ahmed 2017 (15)	3–7 Y	Tonsillectomy and/or Adenoidectomy	86	Sev Intubation	DEX (41):1 ug/kg intranasal; NS (41):1 ml intranasal	ABCDEF
Song 2016 (22)	2–6 Y	Strabismus surgery	103	Sev, N ₂ O LMA	DEX1(14):0.25 ug/kg iv; DEX2(14):0.5 ug/kg iv; DEX3v (27):1 ug/kg iv; NS (14): iv	ACDF
Ali 2016 (11)	3–6 Y	Orthopedic surgery	90	Sev Intubation	DEX (19):0.3 ug/kg iv; Ketofol (19): ketamine 0.25 mg/kg and Propofol 1 mg/kg iv; NS (19):10 ml iv	AD
Mukherjee 2015 (19)	3–7 Y	Day care surgery	80	Sev Intubation	DEX (24):1 ug/kg intranasal; Clonidine (24):4 ug/kg intranasal	ABCDEF
Liu 2015 (27)	2–12 Y	Achilles-tendon lengthening	80	Sev Intubation	DEX (24):0.5 ug/kg iv; NS (24):10 ml iv	ADEF
Sheta 2014 (28)	3–6 Y	Dental rehabilitation	72	Sev, N ₂ O Intubation	DEX (29):1 ug/kg intranasal; Midazolam (29):0.2 mg/kg	ABCE
Ali 2013 (8)	2–6 Y	Adenotonsillectomy	120	Sev, N ₂ O Intubation	DEX (24):0.3 ug/kg iv; Propofol (24):1 mg/kg iv; NS (24):10 ml iv	ABDEF
Meng 2012 (31)	5–14 Y	Tonsillectomy	120	Sev Intubation	DEX1 (24):0.5 ug/kg iv followed by 0.2 ug/kg/h; DEX2 (24):1 ug/kg followed by 0.4 ug/kg/h; lactated Ringer (24): iv	ADEF
Xu 2012 (32)	3–7 Y	Vitreoretinal surgery	60	Sev, Remifentanil Intubation	DEX (19):0.5 ug/kg, iv; NS (19):10 ml iv	ADE
Asaad 2011 (33)	5–10 Y	Elective surgery	88	Sev, N ₂ O Intubation	DEX (19):0.15 ug/kg, iv; Fentanyl (27):1 ug/kg; NS (19):10 ml iv	AEF
lbacache 2004 (14)	1–10 Y	Inguinal hernia repair, orchiopexy, or circumcision	90	Sev, N ₂ O LMA	DEX1(19):0.15 ug/kg, iv; DEX2(19):1 ug/kg; NS (19):10 ml iv	AEF
Olutoye 2011 (34)	3–12 Y	Tonsillectomy and adenoidectomy	109	Sev, N ₂ O Intubation	DEX1(23):0.75 ug/kg, iv; DEX2(32):1 ug/kg,iv;Morphine1(19):50 ug/kg iv; Morphine2(23):100 ug/kg iv	AB
Li 2018 (25)	2–7 Y	Adenoidectomy with or without tonsillectomy	90	Propofol, Remifentanil Intubation	DEX1(19):1 ug/kg, iv; DEX2(19):2 ug/kg, iv; NS (19):1 ml iv	А

(Continued)

TABLE 1 | Continued

Study ID	Age	Surgery type	Sample size	Anesthesia	Groups	Outcome
Kim 2014 (16)	1–5 Y	Strabismus Surgery	94	Des Intubation	DEX (42):0.2 ug/kg/h; NS (42): iv	ACDEF
Patel 2010 (20)	2–10 Y	Tonsillectomy and adenoidectomy	122	Sev, N ₂ O Intubation	DEX (61):2 ug/kg followed by 0.7 ug/kg/h; Fentanyl (61):1 ug/kg iv	ACDE
Koceroglu 2020 (21)	2–9 Y	Adenotonsillectomy	60	Sev, N ₂ O Intubation	DEX (19):1 ug/kg iv; Tramadol (19):1.5 mg/kg iv	ABDE
Akin 2011 (17)	2–9 Y	Adenotonsillectomy	90	Sev, N ₂ O Intubation	DEX (43):1 ug/kg intranasal; Midazolam (43):0.2 mg/kg intranasal	ABCD
Kim 2014 (38)	1–5 Y	Hernioplasty or orchiopexy	40	Sev LMA	DEX (11):1 ug/kg followed by 0.1 ug/kg/h; NS (11): same amount IV	AD
Shukry 2005 (39)	1–10 Y	Outpatient surgery	46	Sev Intubation	DEX (13):0.2 ug/kg/h infusion; NS (13): volume-matched iv	ADF
Surana 2017 (40)	6 M-12 Y	Cleft palate surgery	60	lso, N ₂ O Intubation	DEX (19):1 ug/kg followed by 0.5 ug/kg/h; Midazolam (19):0.05 mg/kg iv	ACDE
Tsiotou 2018 (24)	3–14 Y	Tonsillectomy	60	Propofol, Remifentanil Intubation	DEX (28):1 ug/kg iv; NS (31):50 ml iv	ACD
Bhadla 2013 (29)	5–12 Y	Ophthalmic day-care surgery	60	lso Intubation	DEX (19):0.4 ug/kg iv; Midazolam (19):0.04 mg/kg iv	А

A, emergence agitation; B, PONV; C, requiring rescue anesthetic; D, extubation time; E, emergence time; F, Time to discharge from the PACU; M, months; Y, years; DEX, dexmedetomidine; NS, normal saline; LMA, laryngeal mask airway; Sev, sevoflurane; Des, desflurane; Iso, isoflurane.

and Higgins I^2 statistical tests were used to assess the statistical heterogeneity in the pooled results (7). I^2 value was used to determine the level of heterogeneity in results; $0\% \leq I^2 < 25\%$ denoted no heterogeneity; $25\% \leq I^2 < 50\%$, denoted low heterogeneity; $50\% \leq I^2 < 75\%$ denoted medium heterogeneity; and $75\% \leq I^2 \leq 100\%$ denoted high heterogeneity. Data from all eligible RCTs were combined using the Mantel–Haenszel model to calculate the pooled risk ratio (RR) and 95% confidence interval (CI). Meta-analyses were performed using a random-effects model on account of clinical heterogeneity. This model provides an appropriate estimate of the average treatment effect when studies are statistically heterogeneous, and it typically yields relatively wide CIs resulting in a more conservative statistical claim. Statistical significance was set at a value of p < 0.05.

RESULTS

We initially identified 1,309 relevant studies for the analysis, with 591 being excluded for duplication and 647 excluded after screening of title and abstract. Furthermore, 71 potentially eligible articles were reviewed for full texts, of which 36 were excluded for not satisfying the inclusion criteria. Moreover, we could not extract data from two studies. Finally, 33 (8–40) independent studies were included in the meta-analysis. **Figure 1** presents the detailed selection process.

Table 1 summarizes the characteristics of the included trials.All the 33 included trials were published between 2004 and2020. The sample size in the included trials ranged between

36 and 122, and a total of 2,549 subjects. Age of participants ranged from 3 months to 14 years. **Figure 2** presents the risk of bias.

Primary Outcome

EA incidence was reported in all the included studies. The results of EA in 10 studies could not be pooled. Among the included trials, 15 studies compared the efficacy of dexmedetomidine with that of saline in preventing EA incidence, and the total number of reported events in these trials was 327. The reported EA incidences in the included trials were 14.2% (74 out of 522) and 55% (253 out of 460) in the dexmedetomidine and saline groups, respectively. Dexmedetomidine was associated with a significant reduction in the EA incidence, compared with saline (RR 0.29; 95% CI 0.22–0.37; p < 0.00001) (Figure 3), and heterogeneity was not observed ($I^2 = 13\%$). Compared with other anesthetics, dexmedetomidine was not found to significantly reduce the EA incidence (RR 0.89; 95% CI 0.54–1.45; p = 0.63; $I^2 = 39\%$) (Figure 3).

In the subgroup analyses, six studies indicated that dexmedetomidine significantly reduces the EA incidence (RR 0.26; 95% CI 0.18–0.37; p < 0.00001; $I^2 = 7\%$) in adenoidectomy with or without tonsillectomy compared with saline. In addition, two studies indicated that dexmedetomidine reduces the EA incidence in ophthalmologic surgery (RR 0.22; 95% CI 0.12–0.4; p < 0.00001; $I^2 = 0\%$) and orthopedic surgery (RR 0.28; 95% CI 0.16–0.51; p < 0.0001; $I^2 = 0\%$) compared with saline, respectively (**Figure 4**). Moreover, 16 studies, different dosages of dexmedetomidine with that of saline, indicated that each dosage of dexmedetomidine is effective in preventing EA



(**Figure 5**). Finally, two studies compared dexmedetomidine and fentanyl, three studies compared dexmedetomidine and midazolam, and one study compared dexmedetomidine and propofol; morphine, clonidine, kotofol, respectively, showed no significant differences between them in EA incidence (p > 0.05) (**Figure 6**).

Secondary Outcomes

Compared with saline, dexmedetomidine significantly reduced the PONV incidence (RR 0.46; 95% CI 0.3–0.69; p = 0.0002) and the requirement of rescue analgesic (RR 0.29; 95% CI 0.18–0.44; p < 0.00001). Extubation time (MD 0.77; 95% CI 0.22–1.31; p = 0.006) and emergence time (MD 2.18; 95% CI 0.81–3.56; p = 0.002) were longer in the dexmedetomidine group compared with the saline group. Eight studies assessing the time to discharge from the PACU reported no significant difference between the dexmedetomidine and saline groups (MD 2.22; 95% CI –2.29–6.74; p = 0.33) (Figure 7).

Compared with other anesthetics, dexmedetomidine significantly reduced the requirement of rescue analgesic (RR 0.45; 95% CI 0.33–0.61; p < 0.00001). However, no significant differences were observed between the dexmedetomidine and other anesthetics in terms of PONV incidence (RR 0.65; 95% CI 0.42–1.00; p = 0.05), extubation time (MD 0.36; 95% CI –1.62–2.34; p = 0.72), emergence time (MD –0.23; 95% CI –1.66–1.2; p = 0.75), and time to discharge from the PACU (MD 1.08; 95% CI –2.23–4.38; p = 0.52) (**Figure 8**).

Publication Bias

Funnel plots for the primary outcome indicated a slight publication bias (**Figure 9**).

DISCUSSION

This meta-analysis indicates that dexmedetomidine is efficient in preventing EA, avoiding PONV, and alleviating pain in children under general anesthesia compared with saline, although with prolonged emergence time and extubation time. However, time to discharge from PACU was similar in patients after anesthesia with saline and other anesthetics.

EA is one of the most common postoperative complications in pediatric surgery, following general anesthesia. Although many drugs have been applied to prevent EA, consensus on the most effective drug is lacking.

Several studies comparing the efficacy of dexmedetomidine with that of placebo have been published (41, 44, 45). In line with these studies, this meta-analysis demonstrated that compared with saline, intranasal or intravenous administration of dexmedetomidine significantly reduces the EA incidence. Subgroup analyses with different dosages and different operations indicated that each dosage of dexmedetomidine is efficient in preventing EA, compared with saline. Since the optimal dosage of dexmedetomidine for preventing EA could not be deduced from the present analysis, the lowest dose

01 1 0 1	Experim	ental	Contr	ol	184-1-1-4	Risk Ratio	Risk Ratio		
<u>Study or Subgroup</u>	Events	10tal	Events	Total	weight	M-H, Random, 95% CI	M-H, Random, 95% Cl		
Ahmed 2017 3 43 25 43 3.0% 0.12/0.04 0.271									
Anmeu 2017 Dhat 2010	С	43	20	43	3.9% 5.00/	0.12[0.04, 0.37]			
Dial 2010	5	20	13	30	5.0%	0.23 [0.10, 0.33]			
DI 2019 Gular 2005	о Б	20	14	20	5.0%				
lbacache 2003	0	00 60	11	20	5.2%		.		
10acache 2004 1/im (2) 2014	7	47	22	30	5,3%	0.30 [0.10, 0.81]	- _		
Kim (2) 2014 Kim 2014	1	20	11	20	1 0 %				
Li 2016	, 6	40	33	40	5.5%	0.03 [0.01, 0.04]	_		
Liu 2015	0 6	40	21	40	53%	0.10 [0.03, 0.03]	_		
Mukhariga 2015	a	40	14	40	5.3%	0.64 [0.31, 1.31]	_		
Nidhi 2013	0	18	4	18	1.0%	0.04 [0.01, 1.01]	· · · · · · · · · · · · · · · · · · ·		
Shukw 2005	6	23	14	23	5.4%	0.43 [0.20, 0.92]			
Tsintou 2018	6	31	12	29	51%	0.43 [0.20, 0.02]			
Wei 2015	3	20	18	20	4.2%	0.17 [0.16, 0.48]			
Xii 2012	3	30	13	30	3.8%	0.23 [0.07, 0.73]			
Subtotal (95% CI)		522	10	460	67.9%	0.29 [0.22, 0.37]	•		
Tatal avanta	74		253		0.1070	0120 [0122, 0101]			
Lotal events			200						
Heterogeneity: Tau ² =	0.03; Chi ^z	= 16.06	, df = 14	(P = 0.3	31); I ² = 1	3%			
Heterogeneity: Tau ² = Test for overall effect: 1.1.2 Dexmedetomidi	0.03; Chi² Z = 9.84 (F ine versus	= 16.06 P < 0.00 s other d	, df = 14 001) rugs	(P = 0.3	31); I² = 1	3%			
Heterogeneity: Tau ² = Test for overall effect: 1.1.2 Dexmedetomidi Akin 2011	0.03; Chi [≃] Z = 9.84 (F ineversus 8	= 16.06 • < 0.000 • other d 45	, df = 14 001) rugs 5	(P = 0.) 45	31); I² = 1 4.2%	3% 1.60 [0.57, 4.52]			
Heterogeneity: Tau ² = Test for overall effect: 1.1.2 Dexmedetomidi Akin 2011 Ali 2013	0.03; Chi [≥] Z = 9.84 (F ine versus 8 5	= 16.06 < 0.00 other d 45 40	, df = 14 001) rugs 5 13	(P = 0.1 45 40	31); I² = 1 4.2% 4.7%	3% 1.60 [0.57, 4.52] 0.38 [0.15, 0.98]			
Heterogeneity: Tau ² = Test for overall effect: 1.1.2 Dexmedetomidi Akin 2011 Ali 2013 Ali 2016	0.03; Chi≊ Z = 9.84 (F ine versus 8 5 8	= 16.06 P < 0.000 s other d 45 40 30	, df = 14 001) rugs 5 13 5	(P = 0.3 45 40 30	31); I² = 1 4.2% 4.7% 4.4%	3% 1.60 [0.57, 4.52] 0.38 [0.15, 0.98] 1.60 [0.59, 4.33]			
Heterogeneity: Tau ² = Test for overall effect: 1.1.2 Dexmedetomidi Akin 2011 Ali 2013 Ali 2016 Asaad 2011	0.03; Chi² Z = 9.84 (F ine versus 8 5 8 5	= 16.06 < 0.000 other d 45 40 30 30	, df = 14 001) rugs 5 13 5 6	(P = 0.3 45 40 30 28	31); I ² = 1 4.2% 4.7% 4.4% 4.1%	3% 1.60 [0.57, 4.52] 0.38 [0.15, 0.98] 1.60 [0.59, 4.33] 0.78 [0.27, 2.27]			
Heterogeneity: Tau ² = Test for overall effect: 1.1.2 Dexmedetomidi Akin 2011 Ali 2013 Ali 2016 Asaad 2011 Bhadla 2013	0.03; Chi≊ Z = 9.84 (F ine versus 8 5 8 5 8 5 2	= 16.06 < 0.000 other d 45 40 30 30 30	, df = 14 001) rugs 5 13 5 6 4	(P = 0.3 45 40 30 28 30	31); I ² = 1 4.2% 4.7% 4.4% 4.1% 2.5%	3% 1.60 [0.57, 4.52] 0.38 [0.15, 0.98] 1.60 [0.59, 4.33] 0.78 [0.27, 2.27] 0.50 [0.10, 2.53]			
Heterogeneity: Tau ² = Test for overall effect: 1.1.2 Dexmedetomidi Akin 2011 Ali 2013 Ali 2016 Asaad 2011 Bhadla 2013 Erdil 2009	0.03; Chi≊ Z = 9.84 (F ine versus 8 5 8 5 2 5 5	= 16.06 < 0.000 a other d 45 40 30 30 30 30 30	, df = 14 001) rugs 5 13 5 6 4 4	(P = 0.3 45 40 30 28 30 30	31); I ^z = 1 4.2% 4.7% 4.4% 4.1% 2.5% 3.6%	3% 1.60 [0.57, 4.52] 0.38 [0.15, 0.98] 1.60 [0.59, 4.33] 0.78 [0.27, 2.27] 0.50 [0.10, 2.53] 1.25 [0.37, 4.21]			
Heterogeneity: Tau ² = Test for overall effect: 1.1.2 Dexmedetomidi Akin 2011 Ali 2013 Ali 2016 Asaad 2011 Bhadla 2013 Erdil 2009 Olutoye 2011	0.03; Chi ² Z = 9.84 (F ine versus 8 5 8 5 8 5 2 5 9	= 16.06 < 0.000 s other d 45 40 30 30 30 30 30 53	, df = 14 001) rugs 5 13 5 6 4 4 5	(P = 0.3 45 40 30 28 30 30 56	31); I ^z = 1 4.2% 4.7% 4.4% 4.1% 2.5% 3.6% 4.3%	3% 1.60 [0.57, 4.52] 0.38 [0.15, 0.98] 1.60 [0.59, 4.33] 0.78 [0.27, 2.27] 0.50 [0.10, 2.53] 1.25 [0.37, 4.21] 1.90 [0.68, 5.31]			
Heterogeneity: Tau ² = Test for overall effect: 1.1.2 Dexmedetomidi Akin 2011 Ali 2013 Ali 2016 Asaad 2011 Bhadla 2013 Erdil 2009 Olutoye 2011 Sheta 2014	0.03; Chi ² Z = 9.84 (F ine versus 8 5 5 8 5 2 5 9 4	= 16.06 • other d 45 40 30 30 30 30 30 30 30 30 30 3	, df = 14 001) rugs 5 13 5 6 4 4 5 11	(P = 0.3 45 40 30 28 30 30 56 36	31); I ² = 1 4.2% 4.7% 4.4% 4.1% 2.5% 3.6% 4.3% 4.2%	3% 1.60 [0.57, 4.52] 0.38 [0.15, 0.98] 1.60 [0.59, 4.33] 0.78 [0.27, 2.27] 0.50 [0.10, 2.53] 1.25 [0.37, 4.21] 1.90 [0.68, 5.31] 0.36 [0.13, 1.04]			
Heterogeneity: Tau ² = Test for overall effect: 1.1.2 Dexmedetomidi Akin 2011 Ali 2013 Ali 2016 Asaad 2011 Bhadla 2013 Erdil 2009 Olutoye 2011 Sheta 2014 Subtotal (95% CI)	0.03; Chi ² Z = 9.84 (F ine versus 8 5 5 2 5 9 4	= 16.06 • cother d 45 40 30 30 30 30 30 30 30 30 30 3	, df = 14 201) rugs 5 13 5 6 4 4 5 11	(P = 0.3 45 40 30 28 30 56 36 295	4.2% 4.7% 4.4% 4.1% 2.5% 3.6% 4.3% 4.2% 32.1 %	3% 1.60 [0.57, 4.52] 0.38 [0.15, 0.98] 1.60 [0.59, 4.33] 0.78 [0.27, 2.27] 0.50 [0.10, 2.53] 1.25 [0.37, 4.21] 1.90 [0.68, 5.31] 0.36 [0.13, 1.04] 0.89 [0.54, 1.45]			
Heterogeneity: Tau ² = Test for overall effect: 1.1.2 Dexmedetomidi Akin 2011 Ali 2013 Ali 2016 Asaad 2011 Bhadla 2013 Erdil 2009 Olutoye 2011 Sheta 2014 Subtotal (95% CI) Total events	0.03; Chi ² Z = 9.84 (F ine versus 8 5 8 5 2 5 9 4 4	= 16.06 < 0.000 cother d 45 40 30 30 30 30 30 30 30 30 30 3	, df = 14 D01) rugs 5 13 5 6 4 4 5 11 53	(P = 0.3 45 40 30 28 30 30 56 36 295	4.2% 4.7% 4.4% 4.4% 2.5% 3.6% 4.3% 4.2% 32.1 %	3% 1.60 [0.57, 4.52] 0.38 [0.15, 0.98] 1.60 [0.59, 4.33] 0.78 [0.27, 2.27] 0.50 [0.10, 2.53] 1.25 [0.37, 4.21] 1.90 [0.68, 5.31] 0.36 [0.13, 1.04] 0.89 [0.54, 1.45]			
Heterogeneity: Tau ² = Test for overall effect: 1.1.2 Dexmedetomidi Akin 2011 Akin 2013 Ali 2013 Ali 2016 Asaad 2011 Bhadla 2013 Erdil 2009 Olutoye 2011 Sheta 2014 Subtotal (95% CI) Total events Heterogeneity: Tau ² =	0.03; Chi ² Z = 9.84 (F ine versus 8 5 5 2 5 9 4 4 0.19; Chi ²	= 16.06 < 0.00 : other d 30 30 30 30 30 30 30 30 31 : 294 = 11.43	, df = 14 001) rugs 5 13 5 6 4 4 5 11 53 , df = 7 (I	(P = 0.3 45 40 30 28 30 56 295 P = 0.12	4.2% 4.7% 4.4% 4.1% 2.5% 3.6% 4.3% 4.2% 32.1 % 2); I ² = 39	3% 1.60 [0.57, 4.52] 0.38 [0.15, 0.98] 1.60 [0.59, 4.33] 0.78 [0.27, 2.27] 0.50 [0.10, 2.53] 1.25 [0.37, 4.21] 1.90 [0.68, 5.31] 0.36 [0.13, 1.04] 0.89 [0.54, 1.45]			
Heterogeneity: Tau ² = Test for overall effect: 1.1.2 Dexmedetomidi Akin 2011 Ali 2013 Ali 2016 Asaad 2011 Bhadla 2013 Erdil 2009 Olutoye 2011 Sheta 2014 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect:	0.03; Chi ² Z = 9.84 (F ine versus 8 5 8 5 2 5 9 4 4 0.19; Chi ² Z = 0.48 (F	= 16.06 < 0.000 other d 45 40 30 30 30 30 53 36 294 = 11.43 = 0.63)	, df = 14 201) rugs 5 13 5 6 4 4 5 11 53 , df = 7 (I	(P = 0.1 45 40 30 28 30 56 30 56 295 P = 0.1	4.2% 4.7% 4.4% 4.1% 2.5% 3.6% 4.3% 4.2% 32.1% 2); I ² = 39	3% 1.60 [0.57, 4.52] 0.38 [0.15, 0.98] 1.60 [0.59, 4.33] 0.78 [0.27, 2.27] 0.50 [0.10, 2.53] 1.25 [0.37, 4.21] 1.90 [0.68, 5.31] 0.36 [0.13, 1.04] 0.89 [0.54, 1.45] %			
Heterogeneity: Tau ² = Test for overall effect: 1.1.2 Dexmedetomidi Akin 2011 Ali 2013 Ali 2016 Asaad 2011 Bhadla 2013 Erdil 2009 Olutoye 2011 Sheta 2014 Subtotal (95% Cl) Total events Heterogeneity: Tau ² = Test for overall effect: Total (95% Cl)	0.03; Chi ² Z = 9.84 (F ine versus 8 5 5 2 5 9 4 4 0.19; Chi ² Z = 0.48 (F	= 16.06 < 0.00 cother d 45 40 30 30 30 30 53 36 294 = 11.43 > = 0.63 816	, df = 14 201) rugs 5 13 5 6 4 4 5 11 53 , df = 7 (1	(P = 0.3 45 40 30 28 30 56 30 56 295 P = 0.13	4.2% 4.7% 4.4% 4.1% 2.5% 3.6% 4.3% 4.2% 32.1% 2); I ² = 39 100.0 %	3% 1.60 [0.57, 4.52] 0.38 [0.15, 0.98] 1.60 [0.59, 4.33] 0.78 [0.27, 2.27] 0.50 [0.10, 2.53] 1.25 [0.37, 4.21] 1.90 [0.68, 5.31] 0.36 [0.13, 1.04] 0.89 [0.54, 1.45] % 0.40 [0.29, 0.54]			
Heterogeneity: Tau ² = Test for overall effect: 1.1.2 Dexmedetomidi Akin 2011 Ali 2013 Ali 2016 Asaad 2011 Bhadla 2013 Erdil 2009 Olutoye 2011 Sheta 2014 Subtotal (95% Cl) Total events Heterogeneity: Tau ² = Test for overall effect: Total (95% Cl) Total events	0.03; Chi [≠] Z = 9.84 (F ine versus 8 5 5 2 5 9 4 4 0.19; Chi [≠] Z = 0.48 (F	= 16.06 <pre>cother d 45 40 30 30 30 30 53 36 294 = 11.43 = 0.63) 816</pre>	, df = 14 201) rugs 5 13 5 6 4 4 5 11 53 , df = 7 (1 306	(P = 0.3 45 40 30 28 30 56 30 56 295 P = 0.13 755	4.2% 4.7% 4.4% 4.1% 2.5% 3.6% 4.2% 32.1% 2); I ² = 39 100.0%	3% 1.60 [0.57, 4.52] 0.38 [0.15, 0.98] 1.60 [0.59, 4.33] 0.78 [0.27, 2.27] 0.50 [0.10, 2.53] 1.25 [0.37, 4.21] 1.90 [0.68, 5.31] 0.36 [0.13, 1.04] 0.89 [0.54, 1.45] % 0.40 [0.29, 0.54]			
Heterogeneity: Tau ² = Test for overall effect: 1.1.2 Dexmedetomidi Akin 2011 Ali 2013 Ali 2016 Asaad 2011 Bhadla 2013 Erdil 2009 Olutoye 2011 Sheta 2014 Subtotal (95% Cl) Total events Heterogeneity: Tau ² = Test for overall effect: Total (95% Cl) Total events Heterogeneity: Tau ² =	0.03; Chi ² Z = 9.84 (F ine versus 8 5 2 5 9 4 4 0.19; Chi ² Z = 0.48 (F 120 0.31; Chi ²	= 16.06 <pre>c < 0.00 c other d</pre>	, df = 14 201) rugs 5 13 5 6 4 4 5 11 53 , df = 7 (1 306 , df = 22	(P = 0.3 45 40 30 28 30 56 295 P = 0.1 7 55 (P = 0.1	4.2% 4.7% 4.4% 4.4% 2.5% 3.6% 4.2% 4.2% 32.1% 2); I ² = 39 100.0%	3% 1.60 [0.57, 4.52] 0.38 [0.15, 0.98] 1.60 [0.59, 4.33] 0.78 [0.27, 2.27] 0.50 [0.10, 2.53] 1.25 [0.37, 4.21] 1.90 [0.68, 5.31] 0.36 [0.13, 1.04] 0.36 [0.54, 1.45] % 0.40 [0.29, 0.54]			
Heterogeneity: Tau ² = Test for overall effect: 1.1.2 Dexmedetomidi Akin 2011 Ali 2013 Ali 2016 Asaad 2011 Bhadla 2013 Erdil 2009 Olutoye 2011 Sheta 2014 Subtotal (95% Cl) Total events Heterogeneity: Tau ² = Test for overall effect: Heterogeneity: Tau ² = Test for overall effect:	0.03; Chi ² Z = 9.84 (F ine versus 8 5 2 5 9 4 4 0.19; Chi ² Z = 0.48 (F 120 0.31; Chi ² Z = 5.81 (F	= 16.06 <pre>c < 0.00 c other d 45 40 30 30 30 30 53 36 294 = 11.43 P = 0.63 816 = 51.44 P < 0.00 </pre>	, df = 14 001) rugs 5 13 5 6 4 4 5 11 53 , df = 7 (1 306 , df = 22 001)	(P = 0.1 45 40 30 28 30 56 295 P = 0.1 7 55 (P = 0.1	4.2% 4.7% 4.4% 4.4% 2.5% 3.6% 4.2% 32.1% 2); I ² = 39 100.0%	3% 1.60 [0.57, 4.52] 0.38 [0.15, 0.98] 1.60 [0.59, 4.33] 0.78 [0.27, 2.27] 0.50 [0.10, 2.53] 1.25 [0.37, 4.21] 1.90 [0.68, 5.31] 0.36 [0.13, 1.04] 0.89 [0.54, 1.45] % 0.40 [0.29, 0.54] = 57%	0.01 0.1 1 10 100		

dexmedetomidine when compared to saline; there was no significant difference between dexmedetomidine and other drugs.

according to the patients' physical condition and operation type can be considered to avoid the side effects of dexmedetomidine. More prospective studies comparing the effects of different dosages of dexmedetomidine on EA are required to establish the optimal dose. Dexmedetomidine used in tonsillectomy, adenoidectomy, ophthalmologic, and orthopedic surgeries lower the EA incidence compared with saline, which is consistent with the findings of Cho et al. (43), Jiao et al. (46), and Tan et al. (42). Tonsillectomy with or without adenoidectomy is commonly associated with throat pain and discomfort, and the EA risk associated with this procedure is up to 55.88% and may involve "a sense of suffocation" because of edema, difficulty in swallowing, and nausea. Dexmedetomidine, through adequate analgesia and sedation, significantly decreases the EA occurrence, and can be widely used in suitable patients. Dexmedetomidine can reduce EA incidence not only in children receiving general anesthesia but also in children undergoing magnetic resonance imaging, without hemodynamic or respiratory distress that prolong the time to discharge from the hospital (47). This meta-analysis indicates that the PONV event is reduced in children following dexmedetomidine anesthesia compared with that in children under saline administration; however, a meta-analysis published in 2014 could not establish the efficacy of dexmedetomidine was also found to significantly reduce the requirement of rescue analgesic, which is consistent with the findings of Cho et al. (43) and Jun et al. (48). Inadequate analgesia is one of the factors contributing to postoperative

	Experim	ental	Contr	ol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
8.1.1 tonsillectomy a	nd/or ader	noidecto	my				
Ahmed 2017	3	43	25	43	5.9%	0.12 [0.04, 0.37]	
Ali 2013	5	40	22	40	9.8%	0.23 [0.10, 0.54]	
Erdil 2009	5	30	14	30	9.4%	0.36 [0.15, 0.87]	
Guler 2005	5	30	17	30	10.0%	0.29 [0.12, 0.69]	
Li 2016	6	40	33	40	13.1%	0.18 [0.09, 0.39]	
Tsiotou 2018	6	31	12	29	10.5%	0.47 [0.20, 1.08]	
Subtotal (95% CI)		214		212	58.6%	0.26 [0.18, 0.37]	•
Total events	30		123				
Heterogeneity: Tau² =	0.02; Chi ^z	²= 5.40,	df = 5 (P	= 0.37)); l² = 7%		
Test for overall effect:	Z = 7.17 (F	P < 0.00	001)				
8.1.2 ophthalmologic	surgery						
Kim (2) 2014	7	47	33	47	14.7%	0.21 [0.10, 0.43]	
Xu 2012	3	30	13	30	5.6%	0.23 [0.07, 0.73]	
Subtotal (95% CI)		77		77	20.3%	0.22 [0.12, 0.40]	•
Total events	10		46				
Heterogeneity: Tau² =	0.00; Chi ^a	²= 0.01,	df = 1 (P	= 0.90)); I² = 0%		
Test for overall effect:	Z = 4.97 (F	P < 0.00	001)				
8.1.3 orthopedic surg	jery						
Ali 2016	8	30	27	30	20.1%	0.30 [0.16, 0.54]	
Nidhi 2013	0	18	4	18	0.9%	0.11 [0.01, 1.92]	
Subtotal (95% CI)	_	48		48	21.1%	0.28 [0.16, 0.51]	-
Total events	8		31				
Heterogeneity: Tau*=	0.00; Chi*	[•] = 0.46,	df = 1 (P	= 0.50)); I* = 0%		
Test for overall effect:	Z = 4.17 (F	^o < 0.001	01)				
Total (95% Cl)		339		337	100.0%	0.25 [0.19, 0.33]	•
Total events	48		200			0.20 [0.10, 0.00]	
Heterogeneity: Tau ² =	0.00: Chi ²	'= 6.28	df = 9/P	$= 0.71^{\circ}$	r: I≊ = 0%		
Test for overall effect:	7 = 9.86 /F	⊃ < ∩ ∩∩i	0.01)	0.11,	,,		0.01 0.1 1 10 100
Test for subaroun diff	erences: (chi²=Ω₄	41 df= 7	$(\mathbf{P} = 0)$	82) F=0	196	Dexmedetomidine saline
, correr oungroup unit	o, on 600. C					~~~	
FIGURE 4 Incidence of EA i	in different s	surgeries:	dexmede	etomidin	e vs. saline	Э.	

agitation. Dexmedetomidine activates the α (2)-adrenergic receptor located in the presynaptic and posterior membranes of the spinal cord and inhibits the peripheral nerve fibers A and C which may contribute to the decrease in the demand for a rescue analgesic. Time to emergence and extubation were longer in the dexmedetomidine group compared with saline groups; heterogeneity was observed, may have originated from the study of Yang, wherein children with cerebral palsy were included, and dexmedetomidine reduced the sevoflurane mandate during surgery, thereby decreasing the emergence time and extubation time, which contradict the findings of other studies (27). Unexpectedly, no significant difference was observed in the time to discharge from the PACU between the dexmedetomidine and saline groups; heterogeneity was observed when these studies were pooled owing to the study by Bhat. Overall, we found that dexmedetomidine slightly increases the time to discharge from the PACU by 2.22 min, relative to saline, which is shorter than what was reported in a study by Ni et al. Dexmedetomidine offers favorable analgesia and sedation, and may avoid restlessness, unusual behaviors, such as kicking, shouting, and crying in children, which might account for the reduced stay time in the PACU. Generally, dexmedetomidine is effective in preventing EA, without prolonging the time to discharge from the PACU, and thus, it could decrease the burden on healthcare workers and parents.

Except for the requirement of rescue analgesic, no significant differences were observed between the dexmedetomidine and other anesthetic groups in terms of the EA incidence, PONV event, emergence time, extubation time, and time to discharge from the PACU, which is in line with the findings of Feng et al. (49) and Peng et al. (50). Midazolam, a y-amino-butyric acid receptor inhibitor, is commonly used for premedication in children, which provides effective sedation, anxiolytic effect, and anterograde amnesia; however, it also produces side effects, such as postoperative behavioral changes, cognitive impairment, paradoxical reactions, and respiratory depression (17, 28, 29). Unlike midazolam, dexmedetomidine exerts its hypnotic action through the activation of central pre- and post-synaptic $\alpha(1)$ adrenergic receptors in the locus coeruleus, rather than the cerebral cortex, and induces a natural sleep status in which the patients remain easily arousable and cooperative, and

where the second s	Events	ntal Total E	Contro vents	ol Total	Weight	Risk Ratio M-H, Random, 95% Cl	Risk Ratio M-H, Random, 95% Cl
7.1.1 0.15ug/kg	-						
Asaad 2011	5	30	12	30	4.2%	0.42 [0.17, 1.04]	
Ibacache 2004	5	30	11	30	4.2%	0.45 [0.18, 1.15]	
Subtotal (95% CI)		60		60	8.4%	0.43 [0.23, 0.83]	-
Total events	10		23				
Heterogeneity: Tau* = Test for overall effect:)	0.00; Chi*: Z = 2.51 (P	= 0.02, d1 = 0.01)	r=1 (P:	= 0.90)	; * = 0%		
7.1.2 0.3ug/kg	_						
Ali 2013	5	40	22	40	4.5%	0.23 [0.10, 0.54]	
Ali 2016	8	30	27	30	6.6%	0.30 [0.16, 0.54]	
lbacache 2004	3	30	11	30	3.0%	0.27 [0.08, 0.88]	
Subtotal (95% CI)		100		100	14.2%	0.27 [0.17, 0.43]	•
Total events	16	0.05	60				
Heterogeneity: Tau*= Test for overall effect: 2	0.00; Chi+: Z = 5.59 (P	= 0.25, at < 0.0000	1 = 2 (P =)1)	= 0.88)	; I* = U%		
7.1.3 0.5ua/ka							
Rhat 2018	6	30	13	30	4 8%	0.46 (0.20, 1.05)	
Erdil 2009	5	30	14	30	4.070	0.40 [0.20, 1.03]	.
Guler 2005	5	30	17	30	4.4%	0.30 [0.13, 0.07]	
Liu 2015	с а	40	21	40	5.0%	0.20 [0.12, 0.09]	_ _
Song 2016	11	25	15	25	7 7%	0.23 [0.13, 0.03]	
Xu 2012	3	30	13	20	31%	0.23 [0.42, 1.27]	
Subtotal (95% CI)	5	185	15	185	29.2%	0.40 [0.27, 0.60]	•
Total events	36	105	93	105	23.270	0.40 [0.27, 0.00]	Ť
Heterogeneity Tau ² =	0.07 [.] Chi≅:	= 7 20 dt	55 = 5 (P :	= 0.21)	· I ² = 31%		
Test for overall effect: 2	Z = 4.48 (P	< 0.0000)1)	- 0.21)	,1 = 51.0		
7.1.4 1ug/kg							
Ahmed 2017	3	43	25	43	3.2%	0.12 [0.04, 0.37]	<u> </u>
Bhat 2018	0	30	13	30	0.7%	0.04 [0.00, 0.60]	·
Bi 2019	5	20	14	20	4.9%	0.36 [0.16, 0.80]	
Li 2018	13	30	19	30	7.8%	0.68 [0.42, 1.12]	
Song 2016	6	28	15	25	5.2%	0.36 [0.16, 0.78]	
Tsiotou 2018	6	31	12	29	4.7%	0.47 [0.20, 1.08]	
Subtotal (95% CI)		182		177	26.5%	0.34 [0.18, 0.63]	◆
Total events	33		99				
	55		30				
Heterogeneity: Tau ² = Test for overall effect: 2	0.36; Chi ² : Z = 3.41 (P	= 14.68, (= 0.0008	df = 5 (F 3)	P = 0.01); I² = 66%		
Heterogeneity: Tau ² = Test for overall effect: ; 7.1.5 0.2ug/kg.h	0.36; Chi²÷ Z = 3.41 (P	= 14.68, i = 0.0008	df = 5 (F 3)	P = 0.01); l² = 66%		
Heterogeneity: Tau ² = Test for overall effect: J 7.1.5 0.2ug/kg.h Kim 2 2014	0.36; Chi²: Z= 3.41 (P 7	= 14.68, (= 0.0008 47	df = 5 (F 3) 33	e = 0.01); I ² = 66% 5.7%	0.21 [0.10. 0.43]	
Heterogeneity: Tau ² = Test for overall effect: J 7.1.5 0.2ug/kg.h Kim 2 2014 Li 2016	0.36; Chi²: Z = 3.41 (P 7 6	= 14.68, 4 = 0.0008 47 40	df = 5 (F 3) 33 33	9 = 0.01 47 40); I² = 66% 5.7% 5.4%	0.21 [0.10, 0.43] 0.18 [0.09, 0.39]	<u> </u>
Heterogeneity: Tau ² = Test for overall effect : 7.1.5 0.2ug/kg.h Kim 2 2014 Li 2016 Shukry 2005	0.36; Chi²: Z = 3.41 (P 7 6 6	= 14.68, 4 = 0.0000 47 40 23	df = 5 (F 3) 33 33 14	9 = 0.01 47 40 23); I² = 66% 5.7% 5.4% 5.3%	0.21 [0.10, 0.43] 0.18 [0.09, 0.39] 0.43 [0.20, 0.92]	
Heterogeneity: Tau ² = Test for overall effect : 7.1.5 0.2ug/kg.h Kim 2 2014 Li 2016 Shukry 2005 Subtotal (95% CI)	0.36; Chi [‡] : Z = 3.41 (P 7 6 6	= 14.68, i = 0.0008 47 40 23 110	df = 5 (F 3) 33 33 14	47 40 23 110); I ² = 66% 5.7% 5.4% 5.3% 16.3 %	0.21 [0.10, 0.43] 0.18 [0.09, 0.39] 0.43 [0.20, 0.92] 0.25 [0.15, 0.42]	
Heterogeneity: Tau ² = Test for overall effect: : 7.1.5 0.2ug/kg.h Kim 2 2014 Li 2016 Shukry 2005 Subtotal (95% Cl) Total events	0.36; Chi [‡] : Z= 3.41 (P 7 6 6 19	= 14.68, 1 = 0.0008 47 40 23 110	df = 5 (F 3) 33 33 14 80	47 40 23 110); I ² = 66% 5.7% 5.4% 5.3% 16.3 %	0.21 [0.10, 0.43] 0.18 [0.09, 0.39] 0.43 [0.20, 0.92] 0.25 [0.15, 0.42]	
Heterogeneity: Tau ² = Test for overall effect : 7.1.5 0.2ug/kg.h Kim 2 2014 Li 2016 Shukry 2005 Subtotal (95% Cl) Total events Heterogeneity: Tau ² =	0.36; Chi ² : Z= 3.41 (P 6 6 19 0.06; Chi ² :	= 14.68, 1 = 0.0008 47 40 23 110 = 2.89, dt	33 33 33 14 80 f= 2 (P:	47 40 23 110 = 0.24)); ² = 66% 5.7% 5.4% 5.3% 16.3 % ; ² = 31%	0.21 [0.10, 0.43] 0.18 [0.09, 0.39] 0.43 [0.20, 0.82] 0.25 [0.15, 0.42]	
Heterogeneity: Tau ² = Test for overall effect . 7.1.5 0.2ug/kg.h Kim 2 2014 Li 2016 Shukry 2005 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect .	0.36; Chi [#] : Z = 3.41 (P 6 6 19 0.06; Chi [#] : Z = 5.25 (P	= 14.68, i = 0.0008 47 40 23 110 = 2.89, dt < 0.0000	33 33 33 14 80 7= 2 (P =	47 40 23 110 = 0.24)); I ² = 66% 5.7% 5.4% 5.3% 16.3 % ; I ² = 31%	0.21 [0.10, 0.43] 0.18 [0.09, 0.39] 0.43 [0.20, 0.92] 0.25 [0.15, 0.42]	 ◆
Heterogeneity: Tau ² = Test for overall effect . 7.1.5 0.2ug/kg.h Kim 2 2014 Li 2016 Shukry 2005 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect . 7.1.6 loading dose:1u	0.36; Chi≇: Z= 3.41 (P 7 6 6 19 0.06; Chi≇: Z= 5.25 (P g/kg,maint	= 14.68, = 0.0006 47 40 23 110 = 2.89, df < 0.0000 enance 6	33 33 33 14 80 (= 2 (P =)1) dose:0.1	2 = 0.01 47 40 23 110 = 0.24)); ² = 66% 5.7% 5.4% 5.3% 16.3% ; ² = 31%	0.21 [0.10, 0.43] 0.18 [0.09, 0.39] 0.43 [0.20, 0.92] 0.25 [0.15, 0.42]	 ◆
Heterogeneity: Tau ² = Test for overall effect : 7.1.5 0.2ug/kg.h Kim 2 2014 Li 2016 Shubry 2005 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect : 7.1.6 loading dose:1u Kim 2014	0.36; Chi≆: Z = 3.41 (P 7 6 6 6 19 0.06; Chi≆: Z = 5.25 (P g/kg,maint 1	= 14.68, = 0.0006 47 40 23 110 = 2.89, dt < 0.0000 enance (20 20	33 33 33 14 80 (= 2 (P =)1) (lose:0. 11	2 = 0.01 47 40 23 110 = 0.24) 1ug/kg 20); ² = 669 5.7% 5.4% 5.3% 16.3% ; ² = 31% . h 1.3%	0.21 [0.10, 0.43] 0.18 [0.09, 0.39] 0.43 [0.20, 0.92] 0.25 [0.15, 0.42]	→ →
Heterogeneity: Tau ² = Test for overall effect : 7.1.5 0.2ug/kg.h Kim 2 2014 Li 2016 Shukry 2005 Subtotal (95% Cl) Total events Heterogeneity: Tau ² = Test for overall effect : 7.1.6 loading dose:1u Kim 2014 Subtotal (95% Cl)	0.36; Chi≓: Z = 3.41 (P 7 6 6 0.06; Chi≓: Z = 5.25 (P g/kg,maint 1	= 14.68, i = 0.0000 47 40 23 110 = 2.89, dt < 0.0000 enance 6 20 20	df = 5 (F)) 33 33 14 80 f = 2 (P =)1) dose:0.' 11	2 = 0.01 47 40 23 110 = 0.24) 1ug/kg 20 20); ² = 669 5.7% 5.4% 5.3% 16.3% ; ² = 31% 1.3% 1.3% 1.3%	0.21 [0.10, 0.43] 0.18 [0.09, 0.39] 0.43 [0.20, 0.92] 0.25 [0.15, 0.42] 0.09 [0.01, 0.64] 0.09 [0.01, 0.64]	
Heterogeneity: Tau ² = Test for overall effect : 7.1.5 0.2ug/kg.h Kim 2 2014 Li 2016 Shukry 2005 Subtotal (95% Cl) Total events Heterogeneity: Tau ² = Test for overall effect : 7.1.6 loading dose:1u Kim 2014 Subtotal (95% Cl) Total events	0.36; Chi≄: Z = 3.41 (P 7 6 6 6 19 0.06; Chi≄: Z = 5.25 (P g/kg,maint 1 1	= 14.68, i = 0.0000 47 40 23 110 = 2.89, df < 0.0000 enance (20 20	df = 5 (F)) 33 33 14 80 f = 2 (P =)1) 10 11 11	47 40 23 110 = 0.24) 1ug/kg 20 20); ² = 669 5.7% 5.4% 5.3% 16.3% ; ² = 31% h 1.3% 1.3%	0.21 [0.10, 0.43] 0.18 [0.09, 0.39] 0.43 [0.20, 0.92] 0.25 [0.15, 0.42] 0.09 [0.01, 0.64] 0.09 [0.01, 0.64]	
Heterogeneity: Tau ² = Test for overall effect : 7.1.5 0.2ug/kg.h Kim 2 2014 Li 2016 Shukry 2005 Subtotal (95% Cl) Total events Heterogeneity: Tau ² = Test for overall effect : 7.1.6 loading dose:1u Kim 2014 Subtotal (95% Cl) Total events Heterogeneity: Not ap Heterogeneity: Not ap	0.36; Chi≓: Z = 3.41 (P 7 6 6 7 8 0.06; Chi≓: Z = 5.25 (P g/kg,maint 1 1 0.01(cable 7 = 2.41 (C	= 14.68, = = 0.0006 47 40 23 110 = 2.89, dt < 0.0000 enance (20 20 = 0.020	df = 5 (F) 33 33 14 80 f = 2 (P : 11) 10 11 11	2 = 0.01 47 40 23 110 = 0.24) 1ug/kg 20 20); ²= 669 5.7% 5.4% 5.3% 16.3% ; ² = 31% 1.3% 1.3%	0.21 [0.10, 0.43] 0.18 [0.09, 0.39] 0.43 [0.20, 0.92] 0.25 [0.15, 0.42] 0.09 [0.01, 0.64] 0.09 [0.01, 0.64]	
Heterogeneity: Tau ² = Test for overall effect: . 7.1.5 0.2ug/kg.h Kim 2 2014 Li 2016 Shukry 2005 Subtotal (95% Cl) Total events Heterogeneity: Tau ² = Test for overall effect: . 7.1.6 loading dose:1u Kim 2014 Subtotal (95% Cl) Total events Heterogeneity: Not ap Test for overall effect: . 7.1.7 logeneity: Not ap	0.36; Chi≇: Z = 3.41 (P 7 6 6 7 8 9 0.06; Chi≇: Z = 5.25 (P 9/kg,maint 1 1 1 1 0licable Z = 2.41 (P	= 14.68, (= 0.0006 47 40 23 110 = 2.89, df < 0.0000 enance (20 20 = 0.02)	df = 5 (F)) 33 33 14 80 f = 2 (P : 11) 10 11 11 11	2 = 0.01 47 40 23 110 = 0.24) 10 20 20); ² = 669 5.7% 5.4% 5.3% 16.3% ; ² = 31% 1.3% 1.3%	0.21 [0.10, 0.43] 0.18 [0.09, 0.39] 0.43 [0.20, 0.92] 0.25 [0.15, 0.42] 0.09 [0.01, 0.64] 0.09 [0.01, 0.64]	•
Heterogeneity: Tau ² = Test for overall effect : 7.1.5 0.2ug/kg.h Kim 2 2014 Li 2016 Shukry 2005 Subtotal (95% Cl) Total events Heterogeneity: Tau ² = Test for overall effect : 7.1.6 loading dose:1u Kim 2014 Subtotal (95% Cl) Total events Heterogeneity: Not ap Test for overall effect : 7.1.7 loading dose:1u Nidel 2012	0.36; Chi≆: Z = 3.41 (P 7 6 6 7 8 9 0.06; Chi [≇] : Z = 5.25 (P g/kg,maint 1 00icable Z = 2.41 (P g/kg,maint	= 14.68, i = 0.0008 47 40 23 110 = 2.89, dt < 0.0000 enance (20 20 = 0.02) enance (af = 5 (F 33 33 14 80 f = 2 (P = 11) 10 11 11 11 11	47 40 23 110 = 0.24) 1ug/kg 20 20); ² = 669 5.7% 5.4% 5.3% 16.3% ; ² = 31% 1.3% 1.3%	0.21 [0.10, 0.43] 0.18 [0.09, 0.39] 0.43 [0.20, 0.92] 0.25 [0.15, 0.42] 0.09 [0.01, 0.64] 0.09 [0.01, 0.64]	•
Heterogeneity: Tau ² = Test for overall effect . 7.1.5 0.2ug/kg.h Kim 2 2014 Li 2016 Shukry 2005 Subtotal (95% Cl) Total events Heterogeneity: Tau ² = Test for overall effect . 7.1.6 loading dose:1u Kim 2014 Subtotal (95% Cl) Total events Heterogeneity: Not ap Test for overall effect . 7.1.7 loading dose:1u Nidhi 2013	0.36; Chi [≇] : Z = 3.41 (P 7 6 6 7 8 9 0.06; Chi [≇] : Z = 5.25 (P g/kg,maint 1 1 1 0licable Z = 2.41 (P g/kg,maint 0	= 14.68, i = 0.0008 47 40 23 110 = 2.89, dt < 0.0000 enance (20 = 0.02) enance (18	df = 5 (F 3) 33 14 80 (= 2 (P = 11) 11 11 11 40se:0.9	47 40 23 110 = 0.24) 1ug/kg 20 20 5ug/kg 18); ² = 669 5.7% 5.4% 5.3% 16.3% (1 ² = 31% 1.3% 1.3% 1.3%	0.21 [0.10, 0.43] 0.18 [0.09, 0.39] 0.43 [0.20, 0.92] 0.25 [0.15, 0.42] 0.09 [0.01, 0.64] 0.09 [0.01, 0.64]	•
Heterogeneity: Tau ² = Test for overall effect : 7.1.5 0.2ug/kg.h Kim 2 2014 Li 2016 Shukry 2005 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect : 7.1.6 loading dose:1u Kim 2014 Subtotal (95% CI) Total events Heterogeneity: Not ap Test for overall effect : 7.1.7 loading dose:1u Nidhi 2013 Subtotal (95% CI)	0.36; Chi ^p : Z = 3.41 (P 7 6 6 7 8 9 0.06; Chi ^p : Z = 5.25 (P g/kg,maint 1 0licable Z = 2.41 (P g/kg,maint 0	= 14.68, i = 0.0006 47 40 23 110 = 2.89, dt < 0.0000 enance (20 20 = 0.02) enance (18 18	df = 5 (F)) 33 33 14 80 (= 2 (P =)1) 11 11 11 11 11 11 11	47 40 23 110 = 0.24) 1ug/kg 20 20 5ug/kg 18 18); ² = 669 5.7% 5.4% 5.3% 16.3% ; ² = 31% 1.3% 1.3% 1.3% 1.3%	0.21 [0.10, 0.43] 0.18 [0.09, 0.39] 0.43 [0.20, 0.92] 0.25 [0.15, 0.42] 0.09 [0.01, 0.64] 0.09 [0.01, 0.64] 0.11 [0.01, 1.92] 0.11 [0.01, 1.92]	•
Heterogeneity: Tau ² = Test for overall effect: : 7.1.5 0.2ug/kg.h Kim 2 2014 Li 2016 Shukry 2005 Subtotal (95% Cl) Total events Heterogeneity: Tau ² = Test for overall effect: : 7.1.6 loading dose:1u Kim 2014 Subtotal (95% Cl) Total events Heterogeneity: Not ap Test for overall effect: : 7.1.7 loading dose:1u Nidhi 2013 Subtotal (95% Cl) Total events	0.36; Chi ² : Z = 3.41 (P 7 6 6 19 0.06; Chi ² : Z = 5.25 (P g/kg,maint 1 1 1 1 1 1 1 1 1 1 1 1 1	= 14.68, i = 0.0008 47 40 23 110 = 2.89, dd < 0.0000 enance (20 20 = 0.02) enance (18 18	df = 5 (F 33 33 14 80 (= 2 (P : 11) 11) 11 11 11 4 4 4	47 40 23 110 = 0.24) 1ug/kg 20 20 5ug/kg 18 18); ² = 669 5.7% 5.4% 5.3% 16.3% ; ² = 31% 1.3% 1.3% h 0.6% 0.6%	0.21 [0.10, 0.43] 0.18 [0.09, 0.39] 0.43 [0.20, 0.92] 0.25 [0.15, 0.42] 0.09 [0.01, 0.64] 0.09 [0.01, 0.64] 0.11 [0.01, 1.92] 0.11 [0.01, 1.92]	
Heterogeneity: Tau ² = Test for overall effect : 7.1.5 0.2ug/kg.h Kim 2 2014 Li 2016 Shukry 2005 Subtotal (95% Cl) Total events Heterogeneity: Tau ² = Test for overall effect : 7.1.6 loading dose:1u Kim 2014 Subtotal (95% Cl) Total events Heterogeneity: Not ap Test for overall effect : 7.1.7 loading dose:1u Nidhi 2013 Subtotal (95% Cl) Total events Heterogeneity: Not ap Test for overall effect :	0.36; Chi≆: Z = 3.41 (P 7 6 6 19 0.06; Chi≆: Z = 5.25 (P g/kg,maint 1 1 1 1 1 1 1 2 Z = 2.41 (P g/kg,maint 0 0 0 0 0 0 0 0 0 0 0 0 0	= 14.68, i = 0.0006 47 40 23 110 = 2.89, dt < 0.0000 enance (20 20 = 0.02) enance (18 18 = 0.13)	33 33 14 80 (= 2 (P: 11) 11 11 11 40se:0. 4	47 40 23 110 = 0.24) 1ug/kg 20 5ug/kg 18 18); ² = 669 5.7% 5.4% 5.3% 16.3% ; ² = 31% 1.3% 1.3% 1.3% 0.6%	0.21 [0.10, 0.43] 0.18 [0.09, 0.39] 0.43 [0.20, 0.92] 0.25 [0.15, 0.42] 0.09 [0.01, 0.64] 0.09 [0.01, 0.64] 0.11 [0.01, 1.92] 0.11 [0.01, 1.92]	
Heterogeneity: Tau ² = Test for overall effect. 7.1.5 0.2ug/kg.h Kim 2 2014 Li 2016 Shukry 2005 Subtotal (95% Cl) Total events Heterogeneity: Tau ² = Test for overall effect. 7.1.6 loading dose:1u Kim 2014 Subtotal (95% Cl) Total events Heterogeneity: Not ap Test for overall effect. 7.1.7 loading dose:1u Nidhi 2013 Subtotal (95% Cl) Total events Heterogeneity: Not ap Test for overall effect.	0.36; Chi≆: Z = 3.41 (P 7 6 6 19 0.06; Chi²: Z = 5.25 (P g/kg,maint 1 1 0licable Z = 2.41 (P g/kg,maint 0 0 0licable Z = 1.51 (P	= 14.68, i = 0.0008 47 40 23 110 = 2.89, dt < 0.0000 enance 6 20 20 = 0.02) enance 6 18 18 18 = 0.13)	33 33 14 80 (= 2 (P :)1) 10 10 11 11 11 4 4 4	47 40 23 110 = 0.24) 1ug/kg 20 20 5ug/kg 18 18); ² = 669 5.7% 5.4% 5.3% 16.3% ()² = 31% 1.3% 1.3% 1.3%	0.21 [0.10, 0.43] 0.18 [0.09, 0.39] 0.43 [0.20, 0.92] 0.25 [0.15, 0.42] 0.09 [0.01, 0.64] 0.09 [0.01, 0.64] 0.11 [0.01, 1.92] 0.11 [0.01, 1.92]	
Heterogeneity: Tau ² = Test for overall effect : 7.1.5 0.2ug/kg.h Kim 2 2014 Li 2016 Shukry 2005 Subtotal (95% Cl) Total events Heterogeneity: Tau ² = Test for overall effect : 7.1.6 loading dose:1u Kim 2014 Subtotal (95% Cl) Total events Heterogeneity: Not ap Test for overall effect : 7.1.7 loading dose:1u Nidhi 2013 Subtotal (95% Cl) Total events Heterogeneity: Not ap Test for overall effect : 7.1.8 0.8ug/kg.min Wei : 2015	0.36; Chi≆: Z = 3.41 (P 7 6 6 19 0.06; Chi≆: Z = 5.25 (P g/kg,maint 1 1 1 1 1 1 2 2.41 (P 0 0 0 0 0 0 0 0 0 0 0 0 0	= 14.68, i = 0.0006 47 40 23 110 = 2.89, dt < 0.0000 enance (20 20 = 0.02) enance (18 18 = 0.13) 20	33 33 14 80 i= 2 (P: 11) 11 11 11 4 4	47 40 23 110 = 0.24) 10 20 20 5009/kg 18 18); ² = 669 5.7% 5.4% 5.3% 16.3% ; ² = 31% 1.3% 1.3% 1.3%	0.21 [0.10, 0.43] 0.18 [0.09, 0.39] 0.43 [0.20, 0.92] 0.25 [0.15, 0.42] 0.09 [0.01, 0.64] 0.09 [0.01, 0.64] 0.11 [0.01, 1.92] 0.11 [0.01, 1.92]	
Heterogeneily: Tau ² = Test for overall effect : 7.1.5 0.2ug/kg.h Kim 2 2014 Li 2016 Shukry 2005 Subtotal (95% Cl) Total events Heterogeneily: Tau ² = Test for overall effect : 7.1.6 loading dose:1u Kim 2014 Subtotal (95% Cl) Total events Heterogeneily: Not ap Test for overall effect : 7.1.7 loading dose:1u Nidhi 2013 Subtotal (95% Cl) Total events Heterogeneily: Not ap Test for overall effect : 7.1.8 0.8ug/kg.min Wei 2015 Subtotal (95% Cl)	0.36; Chi ² : Z = 3.41 (P 7 6 6 19 0.06; Chi ² : Z = 5.25 (P g/kg,maint 1 1 1 1 1 1 1 1 0 1 2 2.41 (P 0 0 0 0 0 0 0 0 0 0 0 0 0	= 14.68, i = 0.0008 47 40 23 110 = 2.89, dd < 0.0000 enance (20 20 = 0.02) enance (18 18 = 0.13) 20 20	33 33 14 80 (= 2 (P: 11) 11 11 11 4 4 4	→ = 0.01 47 40 23 110 = 0.24) 1ug/kg 20 20 5ug/kg 18 18 20 20 20); ² = 669 5.7% 5.4% 5.3% 16.3% 16.3% 1.3% 1.3% 1.3% 0.6% 0.6% 0.6% 3.5%	0.21 [0.10, 0.43] 0.18 [0.09, 0.39] 0.43 [0.20, 0.92] 0.25 [0.15, 0.42] 0.09 [0.01, 0.64] 0.09 [0.01, 0.64] 0.11 [0.01, 1.92] 0.11 [0.01, 1.92] 0.17 [0.06, 0.48]	
Heterogeneity: Tau ² = Test for overall effect : 7.1.5 0.2ug/kg.h Kim 2 2014 Li 2016 Shukry 2005 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect : 7.1.6 loading dose:1u Kim 2014 Subtotal (95% CI) Total events Heterogeneity: Not ap Test for overall effect : 7.1.7 loading dose:1u Nidhi 2013 Subtotal (95% CI) Total events Heterogeneity: Not ap Test for overall effect : 7.1.8 loag/kg.min Wei 2015 Subtotal (95% CI)	0.36; Chi [≠] : Z = 3.41 (P 7 6 6 19 0.06; Chi [≠] : Z = 5.25 (P g/kg,maint 1 1 1 1 1 1 1 1 1 1 1 1 1	= 14.68, i = 0.0008 47 40 23 110 = 2.89, dt < 0.0000 enance 6 20 20 = 0.02) enance 6 18 18 18 = 0.13) 20 20	af = 5 (F 33 33 14 80 (= 2 (P : 11) 11 11 11 11 4 4 4 4	47 40 23 110 = 0.24) 1ug/kg 20 20 5ug/kg 18 18 18 20 20 20 20); ² = 669 5.7% 5.4% 5.3% 16.3% ()² = 31% 1.3% 1.3% 1.3% 1.3% 0.6% 0.6% 3.5% 3.5%	0.21 [0.10, 0.43] 0.18 [0.09, 0.39] 0.43 [0.20, 0.92] 0.25 [0.15, 0.42] 0.09 [0.01, 0.64] 0.09 [0.01, 0.64] 0.11 [0.01, 1.92] 0.11 [0.01, 1.92] 0.11 [0.01, 1.92] 0.17 [0.06, 0.48] 0.17 [0.06, 0.48]	
Heterogeneity: Tau ² = Test for overall effect : 7.1.5 0.2ug/kg.h Kim 2 2014 Li 2016 Shukry 2005 Subtotal (95% Cl) Total events Heterogeneity: Tau ² = Test for overall effect : 7.1.6 loading dose: 1u Kim 2014 Subtotal (95% Cl) Total events Heterogeneity: Not ap Test for overall effect : 7.1.7 loading dose: 1u Nidhi 2013 Subtotal (95% Cl) Total events Heterogeneity: Not ap Test for overall effect : 7.1.8 0.8ug/kg.min Wei 2015 Subtotal (95% Cl) Total events Heterogeneity: Not ap Test for overall effect :	0.36; Chi≆: Z = 3.41 (P 7 6 6 19 0.06; Chi [≆] : Z = 5.25 (P g/kg,maint 1 1 1 1 1 1 2 Z = 2.41 (P g/kg,maint 0 0 0 0 0 0 0 0 0 0 0 0 0	= 14.68, i = 0.0006 47 40 23 110 = 2.89, dt < 0.0000 enance (20 20 = 0.02) enance (18 18 = 0.13) 20 20 = 0.0000	33 33 14 80 i= 2 (P: 11) 11 11 11 11 11 11 11 11 11 11 11 11	47 40 23 110 = 0.24) 1ug/kg 20 20 5ug/kg 18 18 20 20 20); ² = 669 5.7% 5.4% 5.3% 16.3% ; ² = 31% 1.3% 1.3% 1.3% 0.6% 0.6% 3.5% 3.5%	0.21 [0.10, 0.43] 0.18 [0.09, 0.39] 0.43 [0.20, 0.92] 0.25 [0.15, 0.42] 0.09 [0.01, 0.64] 0.09 [0.01, 0.64] 0.11 [0.01, 1.92] 0.11 [0.01, 1.92] 0.17 [0.06, 0.48] 0.17 [0.06, 0.48]	
Heterogeneily: Tau ² = Test for overall effect . 7.1.5 0.2ug/kg.h Kim 2 2014 Li 2016 Shukry 2005 Subtotal (95% CI) Total events Heterogeneily: Tau ² = Test for overall effect . 7.1.6 loading dose:1u Kim 2014 Subtotal (95% CI) Total events Heterogeneily: Not ap Test for overall effect . 7.1.7 loading dose:1u Nidhi 2013 Subtotal (95% CI) Total events Heterogeneily: Not ap Test for overall effect . 7.1.8 0.8ug/kg.min Wei 2015 Subtotal (95% CI) Total events Heterogeneily: Not ap Test for overall effect .	0.36; Chi≆: Z = 3.41 (P 7 6 6 19 0.06; Chi²: Z = 5.25 (P g/kg,maint 1 1 0licable Z = 2.41 (P g/kg,maint 0 0 0 0 0 0 0 0 0 0 0 0 0	= 14.68, i = 0.0008 47 40 23 110 = 2.89, dt < 0.0000 enance (20 20 = 0.02) enance (18 18 18 = 0.13) 20 20 = 0.0009 = 0.0009	aff = 5 (F 33 33 14 80 (= 2 (P :)1) 10 10 11 11 11 11 4 4 4 4 18 18	→ = 0.01 47 40 23 110 = 0.24) 1ug/kg 20 20 5ug/kg 18 18 20); ² = 669 5.7% 5.4% 5.3% 16.3% () ² = 31% 1.3% 1.3% 1.3% 1.3% 0.6% 0.6% 3.5% 3.5%	0.21 [0.10, 0.43] 0.18 [0.09, 0.39] 0.43 [0.20, 0.92] 0.25 [0.15, 0.42] 0.09 [0.01, 0.64] 0.09 [0.01, 0.64] 0.11 [0.01, 1.92] 0.11 [0.01, 1.92] 0.17 [0.06, 0.48] 0.17 [0.06, 0.48]	
Heterogeneity: Tau ² = Test for overall effect : 7.1.5 0.2ug/kg.h Kim 2 2014 Li 2016 Shukry 2005 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect : 7.1.6 loading dose:1u Kim 2014 Subtotal (95% CI) Total events Heterogeneity: Not ap Test for overall effect : 7.1.7 loading dose:1u Nidhi 2013 Subtotal (95% CI) Total events Heterogeneity: Not ap Test for overall effect : 7.1.8 0.8ug/kg.min Wei 2015 Subtotal (95% CI) Total events Heterogeneity: Not ap Test for overall effect : 7.1.8 (0.5% CI) Total events Heterogeneity: Not ap Test for overall effect :	0.36; Chi ² : Z = 3.41 (P 7 6 6 19 0.06; Chi ² : Z = 5.25 (P g/kg,maint 1 1 1 1 1 1 2 2.41 (P 0 0 0 0 0 0 0 0 0 0 0 0 0	= 14.68, i = 0.0006 47 40 23 110 = 2.89, dt = 0.0000 enance (20 20 = 0.02) enance (18 18 = 0.13) 20 20 = 0.0005 695	H = 5 (F 33 33 14 80 = 2 (P: 11) 100se:0. 4 4 18 18 18 18 18	→ = 0.01 47 40 23 110 = 0.24) 1ug/kg 20 20 5ug/kg 18 18 18 20); ² = 669 5.7% 5.4% 5.3% 16.3% ; ² = 31% 1.3% 1.3% 1.3% 0.6% 0.6% 3.5% 3.5%	0.21 [0.10, 0.43] 0.18 [0.09, 0.39] 0.43 [0.20, 0.92] 0.25 [0.15, 0.42] 0.09 [0.01, 0.64] 0.09 [0.01, 0.64] 0.11 [0.01, 1.92] 0.11 [0.01, 1.92] 0.17 [0.06, 0.48] 0.17 [0.06, 0.48]	
Heterogeneily: Tau ² = Test for overall effect : 7.1.5 0.2ug/kg.h Kim 2 2014 Li 2016 Shukky 2005 Subtotal (95% Cl) Total events Heterogeneily: Tau ² = Test for overall effect : 7.1.6 loading dose:1u Kim 2014 Subtotal (95% Cl) Total events Heterogeneily: Not ap Test for overall effect : 7.1.7 loading dose:1u Nidhi 2013 Subtotal (95% Cl) Total events Heterogeneily: Not ap Test for overall effect : 7.1.8 0.8ug/kg.min Wei 2015 Subtotal (95% Cl) Total events Heterogeneily: Not ap Test for overall effect : 7.1.8 0.8ug/kg.min Wei 2015 Subtotal (95% Cl) Total events Heterogeneily: Not ap Test for overall effect :	0.36; Chi≆: Z = 3.41 (P 7 6 6 19 0.06; Chi≆: Z = 5.25 (P g/kg,maint 1 1 1 1 1 1 2 Z = 2.41 (P g/kg,maint 0 0 0 0 0 0 0 0 0 0 0 0 0	= 14.68, i = 0.0006 47 40 23 110 = 2.89, dt < 0.0000 enance (20 20 = 0.02) enance (18 18 = 0.13) 20 20 = 0.0005 695 = 26.28	33 33 14 80 (= 2 (P: 11) 10 10 10 11 11 11 11 11 11 11 11 11 11	47 40 23 110 = 0.24) 1ug/kg 20 20 5ug/kg 18 18 18 20 20 20); ² = 669 5.7% 5.4% 5.3% 16.3% 16.3% 1.3% 1.3% 1.3% 0.6% 0.6% 0.6% 3.5% 3.5% 3.5%	0.21 [0.10, 0.43] 0.18 [0.09, 0.39] 0.43 [0.20, 0.92] 0.25 [0.15, 0.42] 0.25 [0.15, 0.42] 0.09 [0.01, 0.64] 0.09 [0.01, 0.64] 0.11 [0.01, 1.92] 0.11 [0.01, 1.92] 0.17 [0.06, 0.48] 0.17 [0.06, 0.48] 0.17 [0.06, 0.48]	
Heterogeneily: Tau ² = Test for overall effect : 7.1.5 0.2ug/kg.h Kim 2 2014 Li 2016 Shukry 2005 Subtotal (95% Cl) Total events Heterogeneily: Tau ² = Test for overall effect : 7.1.6 loading dose:1u Kim 2014 Subtotal (95% Cl) Total events Heterogeneily: Not ap Test for overall effect : 7.1.7 loading dose:1u Nidhi 2013 Subtotal (95% Cl) Total events Heterogeneily: Not ap Test for overall effect : 7.1.8 0.8ug/kg.min Wei 2015 Subtotal (95% Cl) Total events Heterogeneily: Not ap Test for overall effect : 7.1.8 0.8ug/kg.min Wei 2015 Subtotal (95% Cl) Total events Heterogeneily: Not ap Test for overall effect : Total (95% Cl) Total events Heterogeneily: Not ap Test for overall effect :	0.36; Chi [#] : Z = 3.41 (P 7 6 6 19 0.06; Chi [#] : Z = 5.25 (P g/kg,maint 1 1 1 1 1 1 1 1 1 1 1 1 1	= 14.68, i = 0.0008 47 40 23 110 = 2.89, dt < 0.0000 enance 6 20 20 = 0.02) enance 6 18 18 = 0.13) 20 20 = 0.0008 695 = 36.38, i 0.0008	afr = 5 (F 33 33 14 80 (= 2 (P : 11) 11 11 11 11 11 11 11 11 1	≥ = 0.01 47 40 23 110 = 0.24) 1ug/kg 20 20 5ug/kg 18 18 18 20 20 5ug/kg 690 (P = 0.0); ² = 669 5.7% 5.4% 5.3% 16.3% ; ² = 31% 1.3% 1.3% 1.3% 1.3% 0.6% 0.6% 3.5% 3.5% 3.5% 100.0%	0.21 [0.10, 0.43] 0.18 [0.09, 0.39] 0.43 [0.20, 0.92] 0.25 [0.15, 0.42] 0.09 [0.01, 0.64] 0.09 [0.01, 0.64] 0.11 [0.01, 1.92] 0.11 [0.01, 1.92] 0.17 [0.06, 0.48] 0.17 [0.06, 0.48] 0.13 [0.26, 0.41]	
Heterogeneily: Tau ² = Test for overall effect . 7.1.5 0.2ug/kg.h Kim 2 2014 Li 2016 Shukry 2005 Subtotal (95% CI) Total events Heterogeneily: Tau ² = Test for overall effect . 7.1.6 loading dose:1u Kim 2014 Subtotal (95% CI) Total events Heterogeneily: Not ap Test for overall effect . 7.1.7 loading dose:1u Nidhi 2013 Subtotal (95% CI) Total events Heterogeneily: Not ap Test for overall effect . 7.1.8 0.8ug/kg.min Wei 2015 Subtotal (95% CI) Total events Heterogeneily: Not ap Test for overall effect . 7.1.8 0.8ug/kg.min Wei 2015 Subtotal (95% CI) Total events Heterogeneily: Not ap Test for overall effect . Total events Heterogeneily: Not ap	0.36; Chi [≠] : Z = 3.41 (P 7 6 6 19 0.06; Chi [≠] : Z = 5.25 (P g/kg,maint 1 1 1 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0	= 14.68, i = 0.0006 47 40 23 110 = 2.89, dt = 0.0000 enance 6 20 20 = 0.02) enance 6 18 18 = 0.13) 20 20 = 0.0005 = 36.38, i < 0.0005	str = 5 (F 33 33 14 80 (= 2 (P:)1) 10 11 11 11 11 11 11 4 4 18 18 18 387 37 19 387 37 19 19 10 10 10 10 10 10 10 10 10 10	→ = 0.01 47 40 23 110 = 0.24) 1ug/kg 20 20 5ug/kg 18 18 18 18 20 20 5ug/kg (P = 0.0) (P = 0.0)); ² = 669 5.7% 5.4% 5.3% 16.3% () ² = 31% 1.3% 1.3% 1.3% 1.3% 0.6% 0.6% 3.5% 3.5% 3.5% 100.0%	0.21 [0.10, 0.43] 0.18 [0.09, 0.39] 0.43 [0.20, 0.92] 0.25 [0.15, 0.42] 0.09 [0.01, 0.64] 0.09 [0.01, 0.64] 0.11 [0.01, 1.92] 0.11 [0.01, 1.92] 0.17 [0.06, 0.48] 0.17 [0.06, 0.48] 0.33 [0.26, 0.41] %	↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓

	Dexmedetom	idine	Contro	ol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H. Random, 95% Cl	M-H, Random, 95% Cl
9.1.1 Dexmedetomidi	ne versus Fent	anyl					
Asaad 2011	5	30	6	28	10.6%	0.78 (0.27, 2.27)	
Erdil 2009	5	30	4	30	8.8%	1.25 (0.37, 4.21)	
Subtotal (95% CI)	-	60		58	19.4%	0.96 [0.43, 2.13]	
Total events	10		10			• • •	
Heterogeneity: Tau ² =	0.00: Chi ² = 0.3	3. df = 1	(P = 0.57)	7); ² =	0%		
Test for overall effect: .	Z = 0.11 (P = 0.9	91)					
9.1.2 Dexmedetomidi	ne versus Mida	izolam					
Akin 2011	8	30	5	30	11.6%	1.60 [0.59, 4.33]	
Bhadla 2013	2	30	4	30	5.6%	0.50 [0.10, 2.53]	
Sheta 2014	4	36	11	36	10.9%	0.36 [0.13, 1.04]	
Subtotal (95% CI)		96		96	28.1%	0.70 [0.26, 1.91]	
Total events	14		20				
Heterogeneity: Tau² =	0.42; Chi ² = 4.3	1, df = 2	(P = 0.12)	2); I² =	54%		
Test for overall effect: 2	Z = 0.70 (P = 0.4	48)					
9.1.3 Dexmedetomidi	ne versus Prop	ofol					
Ali 2013	5	40	13	40	12.6%	0.38 [0.15, 0.98]	
Subtotal (95% CI)		40		40	12.6%	0.38 [0.15, 0.98]	
Total events	5		13				
Heterogeneity: Not ap	plicable						
Test for overall effect: 2	Z = 2.01 (P = 0.)	04)					
9.1.4 Dexmedetomidi	ne versus Mor	phine	_				
Olutoye 2011	9	53	5	56	11.2%	1.90 [0.68, 5.31]	
Subtotal (95% CI)		53	_	56	11.2%	1.90 [0.68, 5.31]	
Total events	9		5				
Heterogeneity: Not ap	plicable						
Test for overall effect: 2	Z = 1.23 (P = 0.)	22)					
9.1.5 Dexmedetomidi	ne versus Clon	idine					_
Mukherjee 2015	9	40	14	40	17.0%	0.64 [0.31, 1.31]	
Subtotal (95% CI)		40		40	17.0%	0.64 [0.31, 1.31]	
Total events	9		14				
Heterogeneity: Not ap	plicable						
Test for overall effect:)	Z = 1.21 (P = 0.)	22)					
9.1.6 Dexmedetomidi	ne versus Koto	fol					
Ali 2016	8	30	5	30	11.6%	1.60 [0.59, 4.33]	
Subtotal (95% CI)		30		30	11.6%	1.60 [0.59, 4.33]	
Total events	8		5				
Heterogeneity: Not ap	plicable						
Test for overall effect: J	Z = 0.92 (P = 0.3	36)					
Total (95% CI)		319		320	100.0%	0.84 [0.55, 1.29]	◆
Total events	55		67				
Heterogeneity: Tau ² =	0.14; Chi ² = 12.	16, df =	8 (P = 0.1	4); ² :	= 34%		
Test for overall effect: 2	Z = 0.79 (P = 0.4	43)					Devmedetomidine Other drugs
Test for subaroup diffe	erences: Chi² =	7.50. df:	= 5 (P = ().19). I	²= 33.4%	b	Soundationname Other drugs
GURE 6 Forest plot for ir	ncidence of EA in	dexmed	etomidine	vs. ev	ery other o	drug.	

therefore, it is increasingly used in children (4). Fentanyl, a short-acting opioid analgesic, also produces sedative effects. All the three drugs act on different sites to exert sedative and analgesic effects. Although we observed no significant difference between the effects of these drugs, we recommend that dexmedetomidine is the most suitable option for EA prophylaxis in children as a premedicant because of fewer adverse effects.

Limitations

This meta-analysis has some limitations. First, studies comparing the efficacy of dexmedetomidine with that of midazolam, fentanyl, clonidine, tramadol, and ketofol are limited; a stronger evidence is required to confirm the effectiveness of dexmedetomidine in preventing EA relative to the above drugs. Second, the patients' age in the included studies was variable, which might have caused discrepancy in the

Sacandary outcomer				
Secondary outcomes	Number of trials		RR/MD (95% CI)	Р
PONV	5	+	0.46 (0.30, 0.69)	0.0002
Rescue analgesic	7	*	0.29 (0.18, 0.44)	<0.00001
Extubation time	16	_	0.77 (0.22, 1.31)	0.006
Emergence time	12	-	2.18 (0.81, 3.56)	0.002
Time to discharge from PACU	8	-	- 2.22 (-2.29, 6.74)	0.33
		Favours dexmedetomidine Favours saline		

FIGURE 7 | Forest plot for secondary outcomes (dexmedetomidine vs. saline).



results because pharmacokinetics and pharmacodynamics vary between the age of 3 months and 14 years, which may lead to different results. Third, heterogeneity was observed in some analyses such as in the emergence time, extubation time, and time to discharge from the PACU; however, sensitivity analysis demonstrated that the change in total effects is independent of the inclusion or exclusion of trials.



CONCLUSIONS

Compared with saline, dexmedetomidine decreases the EA risk, PONV incidence, and requirement of rescue analgesic in children undergoing surgery under general anesthesia. Overall, dexmedetomidine is an excellent choice to prevent EA, compared with other drugs.

DATA AVAILABILITY STATEMENT

All datasets generated for this study are included in the article/**Supplementary Material**.

AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

REFERENCES

 Welborn L, Hannallah R, Norden J, Ruttimann U, Callan C. Comparison of emergence and recovery characteristics of sevoflurane, desflurane, and halothane in pediatric ambulatory patients. *Anesth Analg.* (1996) 83:917– 20. doi: 10.1213/0000539-199611000-00005

FUNDING

This study was supported by a grant from the research project of the joint foundation of the Luzhou Government and the Southwest Medical University (2018LZXNYD-ZK02 and 2019LZXNYDJ23), the Sichuan Provincial Science and Technology (2019YJ0692), and the Southwest Medical University research program (2018ZRQN063 and 2019ZQN149).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fped. 2020.580226/full#supplementary-material

- Cravero J, Surgenor S, Whalen K. Emergence agitation in paediatric patients after sevoflurane anaesthesia and no surgery: a comparison with halothane. *Paediatr Anaesth.* (2000) 10:419–24. doi: 10.1046/j.1460-9592.2000.00560.x
- Vlajkovic G, Sindjelic R. Emergence delirium in children: many questions, few answers. Anesth Analg. (2007) 104:84– 91. doi: 10.1213/01.ane.0000250914.91881.a8

- Weerink M, Struys M, Hannivoort L, Barends C, Absalom A, Colin P. Clinical pharmacokinetics and pharmacodynamics of dexmedetomidine. *Clin Pharmacokinet*. (2017) 56:893–913. doi: 10.1007/s40262-017-0507-7
- Moher D, Liberati A, Tetzlaff J, Altman D. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ.* (2009) 339:b2535. doi: 10.1136/bmj.b2535
- Higgins J, Altman D, Gøtzsche P, Jüni P, Moher D, Oxman A, et al. The cochrane collaboration's tool for assessing risk of bias in randomised trials. *BMJ*. (2011) 343:d5928. doi: 10.1136/bmj.d5928
- Higgins J, Thompson S. Quantifying heterogeneity in a meta-analysis. Statist Med. (2002) 21:1539–58. doi: 10.1002/sim.1186
- Ali M, Abdellatif A. Prevention of sevoflurane related emergence agitation in children undergoing adenotonsillectomy: a comparison of dexmedetomidine and propofol. *Saudi J Anaesth.* (2013) 7:296–300. doi: 10.4103/1658-354X.115363
- Peng W, Zhang T. Dexmedetomidine decreases the emergence agitation in infant patients undergoing cleft palate repair surgery after general anesthesia. *BMC Anesthesiol.* (2015) 15:145. doi: 10.1186/s12871-015-0124-7
- Erdil F, Demirbilek S, Begec Z, Ozturk E, Ulger M, Ersoy M. The effects of dexmedetomidine and fentanyl on emergence characteristics after adenoidectomy in children. *Anaesth Intensive Care.* (2009) 37:571– 6. doi: 10.1177/0310057X0903700405
- Ali WA, Mohammed AK, Elshorbagy HM. Dexmedetomidine versus ketofol effect on the incidence of emergence agitation associated with sevofluranebased anesthesia in children undergoing orthopedic surgery. *Egypt J Anaesth.* (2016) 32:277–84. doi: 10.1016/j.egja.2016.01.004
- Gupta N, Rath G, Prabhakar H, Dash H. Effect of intraoperative dexmedetomidine on postoperative recovery profile of children undergoing surgery for spinal dysraphism. J Neurosurg Anesthesiol. (2013) 25:271– 8. doi: 10.1097/ANA.0b013e31828cb6c0
- Cho E, Cha Y, Shim J, Ahn J, Lee S, Ryu K. Comparison of single minimum dose administration of dexmedetomidine and midazolam for prevention of emergence delirium in children: a randomized controlled trial. J Anesth. (2020) 34:59–65. doi: 10.1007/s00540-019-02705-6
- Ibacache M, Muñoz H, Brandes V, Morales A. Single-dose dexmedetomidine reduces agitation after sevoflurane anesthesia in children. *Anesth Analg.* (2004) 98:60–3. doi: 10.1213/01.ANE.0000094947.20838.8E
- El-Hamid A, Yassin H. Effect of intranasal dexmedetomidine on emergence agitation after sevoflurane anesthesia in children undergoing tonsillectomy and/or adenoidectomy. *Saudi J Anaesth.* (2017) 11:137–43. doi: 10.4103/1658-354X.203020
- Kim J, Kim S, Lee J, Kang Y, Koo B. Low-dose dexmedetomidine reduces emergence agitation after desflurane anaesthesia in children undergoing strabismus surgery. Yonsei Med J. (2014) 55:508–16. doi: 10.3349/ymj.2014.55.2.508
- Akin A, Bayram A, Esmaoglu A, Tosun Z, Aksu R, Altuntas R, et al. Dexmedetomidine vs midazolam for premedication of pediatric patients undergoing anesthesia. *Paediatr Anaesth.* (2012) 22:871–6. doi: 10.1111/j.1460-9592.2012.03802.x
- Mizrak A, Erbagci I, Arici T, Avci N, Ganidagli S, Oner U. Dexmedetomidine use during strabismus surgery in agitated children. *Med Principles Pract.* (2011) 20:427–32. doi: 10.1159/000324554
- Mukherjee A, Das A, Basunia S, Chattopadhyay S, Kundu R, Bhattacharyya R. Emergence agitation prevention in paediatric ambulatory surgery: a comparison between intranasal dexmedetomidine and clonidine. *J Res Pharm Pract.* (2015) 4:24–30. doi: 10.4103/2279-042X.150051
- Patel A, Davidson M, Tran M, Quraishi H, Schoenberg C, Sant M, et al. Dexmedetomidine infusion for analgesia and prevention of emergence agitation in children with obstructive sleep apnea syndrome undergoing tonsillectomy and adenoidectomy. *Anesth Analg.* (2010) 111:1004–10. doi: 10.1213/ANE.0b013e3181ee82fa
- 21. Koceroglu I, Devrim S, Bingol Tanriverdi T, Gura Celik M. The effects of dexmedetomidine and tramadol on post-operative pain and agitation, and extubation quality in paediatric patients undergoing adenotonsillectomy surgery: a randomized trial. *J Clin Pharm Ther.* (2020) 45:340–6. doi: 10.1111/jcpt.13080

- Song I, Seo K, Oh A, Baik J, Kim J, Hwang J, et al. Dexmedetomidine injection during strabismus surgery reduces emergence agitation without increasing the oculocardiac reflex in children: a randomized controlled trial. *PLoS ONE*. (2016) 11:e0162785. doi: 10.1371/journal.pone.0162785
- Li H, Zhang L, Shi M, Yang S, Li S, Gao S. Impact of dexmedetomidine on pediatric agitation in the postanesthesia care unit. J Perianesth Nurs. (2018) 33:53–7. doi: 10.1016/j.jopan.2016.03.005
- Tsiotou A, Malisiova A, Kouptsova E, Mavri M, Anagnostopoulou M, Kalliardou E. Dexmedetomidine for the reduction of emergence delirium in children undergoing tonsillectomy with propofol anesthesia: a double-blind, randomized study. *Paediatr Anaesth.* (2018) 28:632–8. doi: 10.1111/pan.13397
- 25. Li L, Wang C, Xu H, Lu H, Zhang H. Effects of different doses of intranasal dexmedetomidine on preoperative sedation and postoperative agitation in pediatric with total intravenous anesthesia undergoing adenoidectomy with or without tonsillectomy. *Medicine*. (2018) 97:e12140. doi: 10.1097/MD.000000000012140
- Bhat R, Mudukanagoudar M, Shetty S, Kamath S. Study of dose related effects of dexmedetomidine on laryngeal mask airway removal in children - a double blind randomized study. *Anaesth Pain Intensive Care.* (2018) 22:368–73.
- Liu Y, Kang D, Na H, Li B, Xu Y, Ni J, et al. Consequence of dexmedetomidine on emergence delirium following sevoflurane anesthesia in children with cerebral palsy. *Int J Clin Exp Med.* (2015) 8:16238–44.
- Sheta S, Al-Sarheed M, Abdelhalim A. Intranasal dexmedetomidine vs midazolam for premedication in children undergoing complete dental rehabilitation: a double-blinded randomized controlled trial. *Paediatr Anaesth.* (2014) 24:181–9. doi: 10.1111/pan.12287
- Bhadla S, Prajapati D, Louis T, Puri G, Panchal S, Bhuva M. Comparison between dexmedetomidine and midazolam premedication in pediatric patients undergoing ophthalmic day-care surgeries. *Anesth Essays Res.* (2013) 7:248–56. doi: 10.4103/0259-1162.118982
- Sun Y, Li Y, Sun Y, Wang X, Ye H, Yuan X. Dexmedetomidine effect on emergence agitation and delirium in children undergoing laparoscopic hernia repair: a preliminary study. J Int Med Res. (2017) 45:973– 83. doi: 10.1177/0300060517699467
- Meng Q, Xia Z, Luo T, Wu Y, Tang L, Zhao B, et al. Dexmedetomidine reduces emergence agitation after tonsillectomy in children by sevoflurane anesthesia: a case-control study. *Int J Pediatr Otorhinolaryngol.* (2012) 76:1036–41. doi: 10.1016/j.ijporl.2012.03.028
- Lili X, Jianjun S, Haiyan Z. The application of dexmedetomidine in children undergoing vitreoretinal surgery. J Anesth. (2012) 26:556– 61. doi: 10.1007/s00540-012-1354-1
- Asaad OM, Hafez M, Mohamed MY, El-mahgoup SS. Comparative study between prophylactic single dose of fentanyl and dexmedetomidine in the management of agitation after sevoflurane anesthesia in children. *Egypt J Anaesth.* (2011) 27:31–7. doi: 10.1016/j.egja.2010.12.005
- 34. Olutoye OA, Glover CD, Diefenderfer JW, McGilberry M, Wyatt MM, Larrier DR, et al. The effect of intraoperative dexmedetomidine on postoperative analgesia and sedation in pediatric patients undergoing tonsillectomy and adenoidectomy. *Anesth Analgesia.* (2010) 111:490–5. doi: 10.1213/ANE.0b013e3181e33429
- 35. Guler G, Akin A, Tosun Z, Ors S, Esmaoglu A, Boyaci A. Singledose dexmedetomidine reduces agitation and provides smooth extubation after pediatric adenotonsillectomy. *Paediatr Anaesth.* (2005) 15:762–6. doi: 10.1111/j.1460-9592.2004.01541.x
- 36. Bi Y, Ma Y, Ni J, Wu L. Efficacy of premedication with intranasal dexmedetomidine for removal of inhaled foreign bodies in children by flexible fiber optic bronchoscopy: a randomized, double-blind, placebo - controlled clinical trial. *BMC Anesthesiol.* (2019) 19:219. doi: 10.1186/s12871-019-0892-6
- Boku A, Hanamoto H, Oyamaguchi A, Inoue M, Morimoto Y, Niwa H. Effectiveness of dexmedetomidine for emergence agitation in infants undergoing palatoplasty: a randomized controlled trial. *Brazil J Anesthesiol.* (2016) 66:37–43. doi: 10.1016/j.bjan.2015.11.001
- Kim N, Kim S, Yoon H, Kil H. Effect of dexmedetomidine on sevoflurane requirements and emergence agitation in children undergoing ambulatory surgery. *Yonsei Med J.* (2014) 55:209–15. doi: 10.3349/ymj.2014.5 5.1.209

- Shukry M, Clyde M, Kalarickal P, Ramadhyani U. Does dexmedetomidine prevent emergence delirium in children after sevoflurane-based general anesthesia? *Paediatr Anaesth.* (2005) 15:1098–104. doi: 10.1111/j.1460-9592.2005.01660.x
- Surana P, Parikh D, Patkar G, Tendolkar B. A prospective randomized controlled double-blind trial to assess the effects of dexmedetomidine during cleft palate surgery. *Korean J Anesthesiol.* (2017) 70:633–41. doi: 10.4097/kjae.2017.70.6.633
- Amorim M, Govêia C, Magalhães E, Ladeira L, Moreira L, Miranda D. Effect of dexmedetomidine in children undergoing general anesthesia with sevoflurane: a meta-analysis. *Brazil J Anesthesiol.* (2017) 67:193– 8. doi: 10.1016/j.bjan.2016.02.015
- Tan D, Xia H, Sun S, Wang F. Effect of ancillary drugs on sevoflurane related emergence agitation in children undergoing ophthalmic surgery: a Bayesian network meta-analysis. *BMC Anesthesiol.* (2019) 19:138. doi: 10.1186/s12871-019-0810-y
- Cho H, Yoon H, Jin H, Hwang S. Efficacy of dexmedetomidine for perioperative morbidities in pediatric tonsillectomy: a metaanalysis. *Laryngoscope.* (2018) 128:E184–E93. doi: 10.1002/lary.26888
- Ni J, Wei J, Yao Y, Jiang X, Luo L, Luo D. Effect of dexmedetomidine on preventing postoperative agitation in children: a meta-analysis. *PLoS ONE*. (2015) 10:e0128450. doi: 10.1371/journal.pone.0128450
- Zhang C, Hu J, Liu X, Yan J. Effects of intravenous dexmedetomidine on emergence agitation in children under sevoflurane anesthesia: a meta-analysis of randomized controlled trials. *PLoS ONE.* (2014) 9:e99718. doi: 10.1371/journal.pone.0099718
- 46. Jiao H, Wang H, Jiang Z, Hu J. Comparative efficacy of ancillary drugs in sevoflurane-related emergence agitation after paediatric adenotonsillectomy:

a Bayesian network meta-analysis. J Clin Pharm Ther. (2020) 45:1039–49. doi: 10.1111/jcpt.13133

- Isik B, Arslan M, Tunga AD, Kurtipek O. Dexmedetomidine decreases emergence agitation in pediatric patients after sevoflurane anesthesia without surgery. *Paediatr Anaesth.* (2006) 16:748– 53. doi: 10.1111/j.1460-9592.2006.01845.x
- Jun J, Kim K, Kim J, Song S. The effects of intranasal dexmedetomidine premedication in children: a systematic review and meta-analysis. *Can J Anaesth.* (2017) 64:947–61. doi: 10.1007/s12630-017-0917-x
- Feng J, Wang X, Lu Y, Pang D, Peng W, Mo J. Effects of dexmedetomidine versus midazolam for premedication in paediatric anaesthesia with sevoflurane: a meta-analysis. J Int Med Res. (2017) 45:912–23. doi: 10.1177/0300060517704595
- Peng K, Wu S, Ji F, Li J. Premedication with dexmedetomidine in pediatric patients: a systematic review and meta-analysis. *Clinics.* (2014) 69:777– 86. doi: 10.6061/clinics/2014(11)12

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Yang, Hu, Peng, Chen, Zhou, Yang, Yang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.